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ABSTRACT
The brain is a complex matrix that is difficult to study. Signaling molecules,
neurotransmitters, are constantly being released and sequestered back into neurons within
milliseconds to facilitate communication and normal function, a process called
neurotransmission. There are few analytical techniques available to selectively probe such
a dynamic system, and even fewer can detect these discrete changes in real-time. In order
to make robust measurements in the brain you need speed, sensitivity, selectivity and small
probe size, which are encompassed by fast-voltammetry with microelectrodes. Traditional
fast-voltammetry at carbon fiber microelectrodes (fast-scan cyclic voltammetry (FSCV))
requires background subtraction to overcome the large capacitive currents generated from
scanning at such a high rate, therefore crucial basal information is lost. To capture this
previously lost information, fast-scan controlled adsorption (FSCAV) was developed for
serotonin detection in vivo. Serotonin is tightly regulated in the brain and thought to mark
affective disorders, therefore it is crucial to develop and cultivate new tools to better
understand this biomarker. Recently, our lab has employed FSCAV to understand niche
mechanisms of action and regulatory processes of the central nervous system regarding
serotonin. Here, we discuss improvements towards basal serotonin detection with FSCAV
by first modifying CFMs to improve sensitivity and stability over prolonged periods of
time and then demonstrate their use in elucidating the effects of antidepressants on tonic
serotonin levels. These efforts have indeed improved our own measurements of serotonin
and have clearly shown that exploiting the in vivo environment can improve biomarker
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detection and thus shows promise as a methodology to be adopted across the fastvoltammetry community.
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Chapter 1: Introduction
NEUROTRANSMISSION
The brain comprises a complex chemical system that changes on a rapid time scale.
These

rapid-fire

Neurotransmission

chemical
is

changes

mediated

are
via

underpinned
small

by

neurotransmission.

molecules

known

as

neurotransmitters/neuromodulators (eg. dopamine (DA), serotonin (5-HT), histamine
(HA)) and occurs though a few general steps. The transmitter is synthesized in the
presynaptic neuron,1 packaged into vesicles and released into the synaptic cleft via
calcium(II)-initiated exocytosis.2 The transmitter then binds to either postsynaptic
receptors or to presynaptic autoreceptors allowing neuronal commination to propagate or
terminate through a given circuit. Finally, the signal is terminated via reuptake of the
neurochemical back into the presynaptic neuron and/or extra- or intra-cellular catabolism.
The fundamental processes neurotransmission are of interest because dysfunctions in
neurotransmission are implicated in neuropsychiatric disorders, such as depression.
Fundamentally, it is important to understand how these neuromodulators function rapidly
(phasic release) and control homeostasis on a slower time scale (ambient levels).

NEUROTRANSMITTERS
Neurotransmission is mediated by essential amino acids (AAs) found in the
extracellular space. AAs have a duality about them, they serve as the building blocks for
neurotransmitters3-5 such as serotonin, dopamine and norepinephrine, and they act on their
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own to propagate signals.6-8 Of notable interest are glutamate, gamma aminobutyric acid
(GABA) and glycine, which play a large role in the mediation of neurotransmission by
functioning as excitatory and inhibitory neurotransmitters.9-11 As glutamate is the precursor
of GABA via glutamate decarboxylase (GAD) mediated metabolism,12, 13 it illustrates the
vital need for these two neurotransmitter systems to have a balanced interaction in order to
maintain homeostasis within the central nervous system (CNS). This homeostasis is
mediated by the release of neuromodulators and is initiated with glutamate by binding to
its receptor types causing a conformational change, an influx of Na+ and efflux of K+ and
hence neuronal signaling.14 In contrast, GABA inhibits signal propagation by
hyperpolarization of the postsynaptic neuron.15 Serotonin and dopamine function via
volume transmission. Unlike the tightly regulated glutamate and GABA, neurochemicals
released via volume transmission can diffuse outside of the synapse and directly influence
(i.e. activate receptors, causing signaling cascades) larger areas of the brain. These types
of messengers are called the neuromodulators.

NEUROTRANSMITTER DYSFUNCTION – THE MONOAMINE
HYPOTHESIS OF DEPRESSSION
When neurotransmission is not at homeostasis, there are serious disease
implications. Since the turn of the 20th century, decades of work have centered on trying
to understand the chemical underpinnings of depression, which is also the focus of our
lab’s work. Primary contenders for being implicated in the depressed state were the
monoamines: serotonin, dopamine and norepinephrine. This idea brought forth “The
Monoamine Hypothesis of Depression” and states that one or a combination of these three
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monoamines are dysregulated in some capacity in the depressed state.22 This hypothesis
was constructed from early pharmaceutical efforts to target these modulators. Clinicians
noted that compounds targeting the serotonergic system were found to provide the most
relief in patients.23 This particular class of drugs became known as selective serotonin
reuptake inhibitors (SSRIs) due to their method of action.22, 24 SSRIs bind to the serotonin
transporters to prevent the reuptake of the serotonin back into the presynaptic neuron; this
is thought to increase the ambient levels of serotonin in the extracellular space25 and thus
has been shown to alleviate depressive symptoms in some patients.26 This improvement in
symptoms, along with SSRI having the least severe side effects27 has placed serotonin as a
key biomarker for depression. Figure 1.1 depicts the pathology for SSRI termination of
reuptake by various transporters: specifically, this model is based off SSRIs mode of action.

Figure 1.1. Antidepressant “Mode of Action” Scheme. This schematic shows a cartoon
of a zoomed in feature of the brain: individual synapses. Pre-antidepressant, there are fewer
red molecules in the synaptic cleft and far fewer escaping into the extracellular space. Upon
antidepressant administration, “post-antidepressant”, the transporters for reuptake of the
red molecules have been blocked, resulting in a large increase to the number of red
molecules in the synaptic and the extracellular space. This is the general mode of action
for SSRIs. (Image made in Biorender).
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Serotonin has 14 receptors types: 7 inhibitory and 7 excitatory G-protein coupled
receptors and 1 excitatory ligand gated ion channel (5-HT3). Most of these receptors are
postsynaptic; however, there are two notable presynaptic receptors: 5-HT1A and 5-HT1B.37
Activation initiates a negative feedback loop, this is one method of serotonin regulation.
Three other major mechanisms exist to prevent the excess release of serotonin into the
cellular space: 1) Uptake 1, serotonin is reuptaken into the presynaptic neuron by serotonin
transporters (SERTS)38-40, 2) Uptake 2, serotonin is reuptaken into other neurons by
monoamine transporters (dopamine transporters (DATS), norepinephrine transporters
(NETS), and organic cation transporters (OCTS)38-41, 3) degradation of serotonin via
monoamine oxidase (MAO).42,

43

Serotonin has long been known to be electroactive,

however, studying this molecule remains difficult. Unlike dopamine, serotonin is tightly
regulated due to this molecule’s natural tendency to be pushed toward reuptake
mechanisms and its metabolism pathways.44

EXISTING ANTIDEPRESSANTS AND FRONTIER TREATMENTS
Drug discovery to treat depression has dwindled since the advent of SSRIs in the
late 70s with the release of Prozac.24 There are two-fold reasons for this: 1) new drugs have
failed to improve the efficacy rates of existing drugs and 2) the full biochemical mechanism
of depression is not known and thus there are no pre-clinical screening tools to test the
potential efficacy of new drugs.68 As of now, a patient presenting with depressive-like
symptoms is given a questionnaire and based of the discretion of the physician a diagnosis
is made and an antidepressant may be prescribed.69 The common classes of antidepressants
include SSRIs, norepinephrine reuptake inhibitors (NRIs), monoamine oxidase inhibitors
(MAOIs) and, more recently, atypical antidepressants. The monoamine hypothesis of
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depression was recently revised to include the interactions of glutamate and GABA with
the emergence of atypical antidepressants like ketamine.70-72 Ketamine, also a drug of
abuse, has emerged as an atypical antidepressant of interest due to its potential rapid relief
of depressive phenotypes.72, 73

NEUROCHEMICAL DETECTION
It is very difficult to develop better drugs for depression because the underlying
chemistry of depression is unknown because it is hard to measure neurotransmitters such
as serotonin. For many decades, electrochemical measurements of serotonin were limited
to ex vivo preparations such as cerebral spinal fluid or tissue slice preparations. To better
understand the dynamics of neuronal communication, neuroscientists and neurochemists
have used a variety of tools to answer some complex questions. Because the in vivo
environment is dynamic and has a small homeostatic window, the tools that are used to
answer these fundamental questions must be cover the “Four S’s” defined by Lama et al:
sensitivity, selectivity, size and speed.53 In order to be an optimal candidate for in vivo
analysis, the technique should meet all 4 of the S’s. Promising techniques have emerged to
look at serotonin’s roles in the brain including microdialysis45-48, chronoamperometry49-51,
and fast voltammetry, 38, 44, 52-58 reviewed below.
Microdialysis
Traditionally, microdialysis has been used in the neuroscience community to
quantify ambient levels of neurotransmitters from the in vivo environment and has been
viewed as the gold-standard technique for ambient detection. This technique works by
perfusing solution to the probe surface and allowing analytes diffuse through semi
permeable membrane. Microdialysis is on its own, a sampling technique and needs to be
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paired with separation technique for true detection and quantification. Though
microdialysis has been proven to be a useful technique, it is not without drawbacks. The
primary issue is the size of the probes themselves, (on average 200-250 µM in diameter).74
The size of this probe causes damage to the brain by being much larger than the
intercapillary distance (~30 µM).75, 76 This damage elicits an immune response and, thus,
microdialysis may not capture the true ambient state for neurotransmission. Fast
voltammetry provides itself as an attractive alternative due to its small probe size,
biocompatibility (carbon probe), and the fast temporal resolution.
Fast-Scan Cyclic Voltammetry (FSCV)
In the early 1980s, the Wightman lab, along with collaborators, created a new niche
tool to study the transmission of dopamine in real time77; they later coined this technique
fast scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes (CFMs).77 CFMs
offer a self-renewing surface, are biocompatible, adsorb cations, and are cheap and
sustainable.78-81 CFMs have been shown to be stable over time thereby making them a great
tool for in vivo studies. Since the advent of FSCV, the method has been employed to study
dopamine neurotransmission dynamics and has also been adapted to study other
neurotransmitters. For example, in 2009, FSCV was first utilized to rapidly measure
serotonin on a sub-second timescale in vivo.52 FSCV detection of serotonin has been used
to study sex differences within the serotonergic system57, to understand reuptake dynamics
of serotonin back in to the presynaptic neuron38, to monitors serotonin’s dynamic phasic
changes to antidepressants44, 54, 57, 58, and to predict tissue architecture58.

6

FSCV detection of serotonin in vivo is accomplished thus; a serotonin selective
waveform (+0.2 V to +1.0V to -0.1V to +0.2V, 1000V/s)21 is applied to an electrode
implanted in the CA2 region of the hippocampus (CA2: AP:-2.91, ML:+3.35, DV-2.5) at
10 Hz. The current is measured at each potential along the ramp and the output is a color
plot generated using custom software. The data are analyzed from false color where green
is indicative of oxidation and blue is indicative of reduction. First extrapolated from
vertical view from the color pot we will see the signature cyclic voltammogram (CV) for
serotonin where its oxidation will occur at 0.7 V while its reduction will occur at 0.0 V.21
The primary purpose this CV serves is to both identify and qualify the that we have found
serotonin. Second, we can extrapolate physiological data by taking a horizontal view of the
color plot. This generates a current vs. time plot can be extrapolated from this color plot
showing the change in the amount of serotonin in the extracellular space over time. This
can be converted into concentration by using a calibration factor.52 The method is
background subtracted due to the very fast scan rate generating a large non-Faradaic
current.82 Therefore, a change must be induced to visualize serotonin’s redox processes:
this is accomplished in vivo by way of electrical stimulation of the medial forebrain bundle
(MFB: AP:-1.58, ML:+1.00, DV:-4.80).52, 82 FSCV is an unquestionably powerful method
for in vivo neurotransmitter analysis, but the major limitation is that it is a backgroundsubtracted technique, meaning one will only be able to see relative changes in serotonin
concentration respect to a low activity state before stimulation (absolute concentration). To
combat this and to measure true extracellular concentration, a new technique was created
in 2013.
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Figure 1.2. FSCV Scheme. To the CFM surface, the serotonin specific waveform is
applied. This is a selective way to monitor the oxidation and reduction of this promiscuous
analyte. A signature CV for serotonin is displayed with in the figure.
Fast-Scan Controlled Adsorption Voltammetry (FSCAV)
Fast-Scan Controlled-Adsorption Voltammetry (FSCAV), was developed first to
measure ambient extracellular levels of dopamine in the absence of an electrical stimulus.83
These in vitro experiments showed promise and FSCAV soon moved in vivo in 2015.55
This method was later modified to measure ambient serotonin.56 FSCAV is analogous to
the principles of stripping voltammetry and is performed in three steps: 1) the serotonin
waveform is applied at 100 Hz to minimize adsorption to the electrode surface; 2) a fixed
potential (0.2 V) is then applied for 10 secs, (the time is calibrated for maximum adsorption
of analyte to the electrodes surface); 3) the waveform is then reapplied and the first
signature cyclic voltammogram collected is used to quantify ambient serotonin
concentration. The concentration is found via post-calibrations of the electrodes. The CVs
are unfolded and the oxidation peak for serotonin is integrated to obtain a charge value
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(pC). Charge is then converted to concentration (nM). The temporal resolution of this
method is 1 minute, and is a great improvement over other techniques for basal
measurements which, on average, have the temporal resolution of 10s of minutes.84-86
Figure 1.3 depicts the 3 steps of FSCAV data acquisition and shows the signature color
plots and cyclic voltammogram for serotonin analysis. By combining FSCV and FSCAV,
we now have a multi-purpose tool for measuring the subtle changes of the serotonergic
system in vivo. This allows for a dual lensed approach to understand serotonins role in
depression and how antidepressants effect this neurotransmitters nuances57.

Figure 1.3. FSCAV Scheme. From left to right, the steps of FSCAV are displayed. 1) 2 s
to minimize adsorption to the electrodes surface. 2) 10 seconds of controlled adsorption
held at 0.2 V to allow for serotonin and other molecules to migrate toward the surface while
repelling major metabolites and interferences such as 5-Hydroxyindoleacetic acid. 3)
Rapid oxidation of serotonin on the electrode surface. This is selective for serotonin
because of the waveform that has been reapplied (the Jackson waveform). An example
color plot, CV and integrated oxidation peak are shown next to the blue arrow of the
FSCAV schematic

These techniques have uncovered a plethora of knowledge of serotonins role and
function in the diseased state. One important nuanced discovery was the ability to
understand the mechanism that controls ambient fluctuations of serotonin oscillations.59, 60
9

Serotonin oscillations are linked to extracellular processes. It is known that too much
serotonin leads to serotonin syndrome, whereas too little serotonin is linked to
depression.61-64 So, there are fine-tuning mechanisms that balance the serotonergic system
to ensure a healthy level is maintained. It is thought that this fine-tuning mechanism can
be related back to the receptors that are found on presynaptic and postsynaptic neurons:
autoreceptors and heteroreceptors, respectively.65-67 These receptors often mediate
modulatory signaling, or in the case of autoreceptors, initiate a feedback loop inhibiting
neurotransmitter release. It has also been noted that these oscillation patterns can be
pharmacologically manipulated.59, 60, 67
Carbon Fiber Surface Modification
It is clear that sensitivity is an issue for detection of low levels of serotonin in vivo,
and while our laboratory’s expertise are these measurements, a more sensitive electrode
may facilitate broader adoption of the method by the greater community. Surface
modification of CFMs has aided the specificity and sensitivity of FSCV measurements.
Serotonin detection has historically employed the use of a cation exchange polymer,
Nafion. This has been used to limit biofouling, repel serotonin’s precursors and
metabolites, and has been shown to increase sensitivity toward serotonin analysis.52, 87, 88
Though Nafion has been shown to initially increase sensitivity toward serotonin, it has
been noted that within the first 20 minutes in a biological matrix there is a 35% loss in
sensitivity.89 Other surface treatments have been explored for improving sensitivity toward
other important monoamines including poly-(3,4-ethylenedioxythiophene) (PEDOT)16,
acid-treatment90, and by over oxidizing the surface of the carbon fiber by extending the
potential widow of the waveform that is being applied past 1.1 V91. However, we have
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found great success by investigating the effects of highly concentrated extracellular amino
acids. Our work has focused on understanding the effects of glutamate on the sensitivity of
our electrode toward serotonin. We have found that by electropolymerizing glutamate to
the electrodes surface that we gain a 2-fold increase in sensitivity. However, we note in our
previous work that glutamate my not be the only contributor to this auspicious
phenomenon. The work in this thesis goes to further study amino acid treatments and
directly uses these novel treatments to improve ambient detection of serotonin.
Scope of Dissertation
This dissertation aims to highlight the versatility, strength and adaptability of fastvoltammetric analysis for the serotonergic system.
Chapter 2: This published article presents a multifaceted approach towards
characterizing glutamate coated CFMs. Imaging techniques confirm the presence of a nonuniformed layer of this new auspicious coating. We also note the increase to analyte
sensitivity (dopamine and serotonin) due to this new surface modifications.
Chapter 3: This chapter describes novel and robust amino acid surface treatment
to improve ambient serotonin detection using FSCAV. This chapter aims to make serotonin
detection and analysis more user-friendly.
Chapter 4: Here we utilize fast voltammetry to study four classes of
antidepressants and their effects on the serotonergic system. This is accomplished by
analyzing stimulated release of the serotonin system and ambient levels of serotonin during
the time of drug administration. We will also describe the response of histamine and its
modulation of serotonin to elicit a mechanism to explain why there is no change in
stimulated release of serotonin is observed, but a robust increase in ambient levels is seen
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upon an acute does of ketamine. This chapter also explores the formation and
characterization of a novel antidepressant, selenium-fluoxetine. This new antidepressant
aims to increase the ambient levels of serotonin by acting as both a traditional
antidepressant and an anti-inflammatory drug. We explore the phasic changes associated
with this novel treatment and compare it to its traditional analog.
Chapter 5: This chapter will introduce serotonin oscillatory patterns and presents
experimental paradigms to increase the frequency of data acquisition during fast-scan
controlled adsorption voltammetry to better define these patterns described. We will also
propose a rational for these tight fluctuations in ambient serotonin via pharmacological and
mathematical means.
Chapter 6: This conclusion chapter will highlight the major findings of this body of
work. First, creating methods for better ambient analysis for serotonin and secondly,
understanding pharmacological manipulations in their phasic release, ambient transmission
and oscillatory changes. Finally, this work shows future direction for faster serotonin basal
data acquisition. In doing so, this work has gone to show the versatility of fast-voltammetry
for serotonin measurements, all while creating more user-friendly methods for the
expansion of serotonin analysis using this unique tool. This chapter will also discuss future
directions.

12

Chapter 2: Glutamate Electropolymerization on Carbon
Increases Analytical Sensitivity to Dopamine and Serotonin:
An Auspicious In Vivo Phenomenon in Mice?1

1

Holmes, J., Witt, C. E., Keen, D., Buchanan, A. M., Batey, L., Hersey, M. & Hashemi P.
Accepted. Glutamate Electropolymerization on Carbon Increases Analytical Sensitivity to
Dopamine and Serotonin: An Auspicious In Vivo Phenomenon in Mice? Analytical
Chemistry
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ABSTRACT
Carbon is the material of choice for electroanalysis of biological systems, being particularly
applicable to neurotransmitter analysis as carbon fiber microelectrodes (CFMs). CFMs are
most often applied to dopamine detection; however, the scope of CFM analysis has rapidly
expanded over the last decade with our laboratory’s focus being on improving serotonin
detection at CFMs, which we achieved in the past via Nafion modification. We began this
present work by seeking to optimize this modification to gain increased analytical
sensitivity toward serotonin under the assumption that exposure of bare carbon to the in
vivo environment rapidly deteriorates analytical performance. However, we were unable
to experimentally verify this assumption and found that electrodes that had been exposed
to the in vivo environment were more sensitive to evoked and ambient dopamine. We
hypothesized that high in vivo concentrations of ambient extracellular glutamate could
polymerize with a negative charge onto CFMs and facilitate response to dopamine. We
verified this polymerization electrochemically and characterized the mechanisms of
deposition with micro- and nano-imaging. Importantly, we identified that the application
of 1.3 V as a positive upper waveform limit is a crucial factor for facilitating glutamate
polymerization, thus improving analytical performance. Critically, information gained
from these dopamine studies were extended to an in vivo environment where a 2-fold
increase in sensitivity to evoked serotonin was achieved. Thus, we present here the novel
finding that innate aspects of the in vivo environment are auspicious for detection of
dopamine and serotonin at carbon fibers, offering a solution to our goal of an improved
fast-scan cyclic voltammetry serotonin detection paradigm.
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INTRODUCTION
Carbon electrodes are uniquely amenable for biological analyses, in particular
detection of neurochemicals in dynamic and complex media. The carbon surface is
biocompatible and versatile (easily fashionable into multiple configurations); a variety of
available carbon forms provide an extensive catalogue of electroanalytical opportunities.1−4
Within neurochemical analysis with this material, carbon fiber microelectrodes (CFMs) are
particularly popular.5,6 For several decades, fast-scan cyclic voltammetry (FSCV) at CFMs
has been employed to study dopamine in the context of pathologies such as addiction and
Parkinson’s disease.7−9 In tandem to this work, the electrochemical properties governing
the FSCV response toward dopamine have been well explored, including the regenerative
ability of carbon, electron transfer kinetics, and adsorption interactions at the carbon fiber
surface interface.10−14
In the last decade, the scope of FSCV has been expanded to analytes other than
dopamine.15−20 In our laboratory, we pioneered FSCV for serotonin and applied these
measurements in vivo.21,22 We have used the method over the last 10 years to investigate
serotonin dynamics in a variety of in vivo scenarios including probing neurochemistry
between sexes, analyzing the effects of antidepressants, investigating mouse models of
disease, and mapping the biochemical architecture in different brain regions.23−27 However,
serotonin detection with CFMs remains niche because serotonin signaling is highly
regulated in vivo, with very low evocable concentrations (low nM range compared to 10
µM evoked dopamine).28 Furthermore, the primary serotonin metabolite, 5-hydroxyindole
acetic acid (5-HIAA), rapidly electropolymerizes on the electrode surface and reduces the
in vivo signal response.22,29−31 Our approach to facilitating serotonin detection has been to
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modify the electrode surface a priori with Nafion, a sulfonated tetrafluoroethylene-based
cation exchange polymer, that preconcentrates serotonin and repels 5-HIAA.22
There has, in recent years, been incongruity in the community about an optimal
Nafion modification procedure,31−35 and there have been reports of alternative polymer
modifications (such as poly(3,4-ethylenedioxythiophene) (PEDOT)).36−38 Thus, we sought
to further improve FSCV’s sensitivity toward serotonin by optimizing a Nafion
modification protocol that would facilitate broader adoption of the method. However,
before we could assess the effects of the polymer coating, we encountered an unusual
phenomenon. Specifically, we were unable to replicate a key assumption in the field that
sensitivity toward monoaminergic cations decreases after electrode implantation into brain
tissue.29,31 We found that after in vivo implantation, electrodes were significantly more
sensitive to dopamine using both FSCV and fast-scan controlled-adsorption voltammetry
(FSCAV). The rationale that electrodes should be less sensitive to dopamine after in vivo
implantation is that polymerization of proteins and metabolites (such as 5-HIAA) makes
the surface less accessible to dopamine. Using the same rationale, we considered which
brain chemicals had the potential to interact with the electrode creating a positive effect for
dopamine detection. Glutamate is a ubiquitous neurotransmitter, present at high
concentrations throughout the brain. This amino acid has been shown previously to
electropolymerize, forming polyglutamic acid (PGA) on carbon surfaces, via a radicalinitiated mechanism.39−42 PGA possesses an overall negative charge at biological pH; thus,
we postulated that a PGA coating on CFMs might improve sensitivity toward dopamine.
Indeed, we found that electrodes electrochemically pretreated in glutamate solution
displayed significantly better analytical responses to dopamine via flow injection analysis
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(FIA). We showed electrochemical evidence for glutamate polymerization onto CFMs and
characterized this film via scanning electron microscopy (SEM) and atomic force
microscopy (AFM). We found that PGA films serve to stabilize or replace Nafion films
with prolonged (>2 h) use, an opportune outcome of the in vivo environment that facilitates
measurements. Finally, we exploited this finding to make a minor modification to our
serotonin detection waveform that resulted in a 2-fold increase in response amplitude
toward serotonin in the CA2 region of the hippocampus.
Given the analytical and morphological similarities between in vivo and PGA
electrodes, we conclude that the high levels of ambient brain glutamate play a role in
enhancing in vivo CFM measurements in the mouse brain. Using this finding, we present
a novel treatment protocol to improve the sensitivity of FSCV toward serotonin in vivo,
which was the original goal of this study. Importantly, this work allows us to suggest that
carbon’s suitability for neurochemical electroanalysis includes an innate and auspicious
interaction of amino acids, like glutamate, with this substrate.

EXPERIMENTAL
General Methods and Materials. Chemicals. Stock solutions were prepared at room
temperature and physiological pH (pH = 7.4) by dissolving glutamic acid and dopamine
hydrochloride (each prepared to a final concentration of 1 µM) into 1× phosphate buffered
saline (PBS) that was diluted from a 10× premixed buffer. Serotonin hydrochloride was
prepared similarly in TRIS hydrocholoride buffer, as described elsewhere.22,26 All
chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise specified.
Liquion (LQ-1105, 5% by weight Nafion) was purchased from Ion Power Solutions (New
Castle, DE, USA).

17

Electrochemistry. Voltammetry was performed on a two electrode system. CFMs were
handmade in-house as previously described.25 Briefly, a single carbon fiber (diameter = 7
µm; Goodfellow Corporation, PA, USA) was aspirated into a glass capillary (1.0 mm
external diameter, 0.5 mm internal diameter, A-M Systems, Inc., Sequim, WA, USA). The
glass capillary was then pulled with a vertical micropipette puller (Narishige, Tokyo,
Japan) to form a carbon-glass seal. The exposed length of the carbon fiber was trimmed to
100 µm under an optical microscope. A Ag wire (A-M systems, WA, USA) was
electroplated with Cl− for 30 s in 0.1 M HCl at 5 V to create a pseudo-Ag/AgCl reference
electrode.
Fast-Scan Cyclic Voltammetry (FSCV). Waveforms were generated using a USB6431DAC/ADC (National Instruments, TX, USA) device. The working electrode was
controlled with a waveform (details on waveforms are specific to each experiment, see
below). The electrode was cycled at 60 Hz for 10 min and then at 10 Hz for 10 min. This
dual frequency strategy speeds up surface preparation but can be achieved with 10 Hz
applied for longer.
Fast-Scan Controlled-Adsorption Voltammetry (FSCAV). FSCAV was performed as
previously described43,44 using a CMOS precision analog switch, ADG419 (Analog
Devices), to control the application of the waveform. The waveform (Dopamine: −0.4 V
to +1.3 V to -0.4 V, scan rate = 1200 V/s) was applied at a frequency of 100 Hz for 2 s and
then held at a constant potential of −0.4 V for 10 s followed by reapplication of the
waveform for the remainder of the total file collection time of 30 s. Cyclic voltammograms
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(CVs) were used for dopamine identification. With FSCAV, the first CV after reapplication
of the waveform with a signature dopamine peak was integrated to determine charge.
Flow Injection Analysis (FIA). FIA was performed in a system, custom-built in-house.
CFMs were inserted into a flangeless short, 1/8 nut (PEEK P-335, IDEX, Middleboro, MA,
USA), exposing a small portion of the tip (2 mm) outside of the nut. An HPLC union
(Elbow PEEK 3432, IDEX, Middleboro, MA, USA) was modified such that the nut
containing the microelectrode was fastened to one end. The out-flowing stream of the FIA
buffer was fastened to the other end of the elbow union. Two holes were drilled into the
union for the incorporation of the pseudo-Ag/AgCl reference electrode and the “waste”
flow stream. A syringe infusion pump (KD Scientific, Model KDS-410, Holliston, MA,
USA) was used to maintain the flow at 2 mL min−1. The analyte was introduced into the
flow stream for 10 s via a six-port HPLC loop injector (Cheminert Valve, VICI, Houston,
TX, USA) resulting in a rectangular plug.
Data Acquisition. FSCV and FSCAV were performed using a Dagan potentiostat, (Dagan
Corporation, Minneapolis, MN, USA), National Instruments multifunction IO device
USB6341 (National Instruments, Austin, TX, USA), WCCV 3.06 software (Knowmad
Technologies LLC, Tucson, AZ, USA), and a Pine Research head stage (Pine Research
Instrumentation, Durham, NC, USA). Data filtering (zero phase, Butterworth, 2 kHz lowpass) and signal smoothing were performed within the WCCV software.
Nafion Electrodeposition. Nafion was electrodeposited on the exposed carbon fiber
surface by applying a constant potential of 1.0 V vs. a pseudo-Ag/AgCl reference electrode
for 30 s. The microelectrode was dried at 70 °C for 10 min and stored for a minimum of
24 h before use.
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Animals. Animal use followed NIH guidelines and complied with the University of South
Carolina Institutional Animal Care and Use Committee under an approved protocol. In vivo
animal experiments were performed as described previously.24 To induce anesthesia, 25%
w/v urethane (Sigma−Aldrich Co.) dissolved in 0.9% NaCl solution (Hospira) was injected
i.p. (7 µL g−1 of body weight). Body temperature was maintained using a heating pad
(Braintree Scientific, Braintree, MA, USA), and stereotaxic surgeries (David Kopf
Instruments, Tujunga, CA, USA) were performed with coordinates taken in reference to
bregma. Specific coordinates used in each experiment can be found below under “Specific
Methods.” A pseudo-Ag/AgCl reference electrode was placed in the contralateral
hemisphere

SPECIFIC METHODS
Figure 2.1. Four-point pre-calibrations were performed before in vivo experiments, and
postcalibrations were performed within 12 h after in vivo experiments where charge (pC
for FSCAV measurements) or current (nA for FSCV measurements) was plotted vs. [DA]
(nM). If the electrodes were left overnight, they were stored dry in a box at constant
temperature. Nafion-coated CFMs were placed in target regions of the mouse brain for in
vivo exposure times of 2 h, typical of an in vivo experiment. For FSCAV data, a Nafioncoated CFM was lowered into the nucleus accumbens core region of the brain (AP: +0.8,
ML: +1.3, DV -4.0). CFMs trimmed to 50 µm were cycled using the modified waveform
described above. For FSCV data, a CFM was lowered until it was fully immersed in the
dorsal striatum (AP: +1.1, ML: +1.7 DV: −2.0) and a triangular waveform was applied
(−0.4 V to 1.3 V to −0.4 V, scan rate = 400 V/s) for 10 min at 60 Hz and 10 min at 10 Hz.
Dopamine release was electrically evoked via MFB stimulation (AP: -1.8, ML: +1.1, DV:
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-4.8). All data were averaged over at least eight electrodes, and the standard error of the
mean was calculated (represented by error bars). A one-tailed paired t-test was utilized to
determine the significance between two points (p < 0.05).
Figure 2.2. The current amplitude and electrode temporal response of various
combinations of CFM pretreatments for dopamine analysis with FIA were compared.
Dopamine analysis was performed using FSCV with the following triangular waveform:
−0.4 V to 1.3 V to −0.4 V at 400 V/s. Each modification protocol was evaluated by
averaging the response of five injections of 1 µM dopamine on four electrodes in the bar
graph. Additionally, the first 3.5 s of the FIA pulse associated with a dopamine injection is
displayed and the slope was calculated by isolating the linear region of the rise curve.
The modification protocols tested were as follows: 1. Bare: unmodified CFM serving as a
control. 2. Glu: glutamate pretreatment and glutamate in FIA calibration buffer. To deposit
PGA, CFMs were dipped in 1 µM glutamate solution (in 1× PBS buffer) and cycled using
the same triangular waveform (−0.4 V to 1.3 V to −0.4 V, 400 V/s) applied during analysis
for 10 min at 60 Hz and 10 min at 10 Hz. 3. In Vivo: in vivo pretreatment. Electrodes were
placed into the cortex of a rodent brain (AP: +0.8, ML: +1.7, DV -0.5) for 20 min and
dopamine was measured immediately thereafter with FIA in PBS only. 4. In Vivo + Glu:
in vivo pretreatment and glutamate in FIA calibration buffer. Electrodes underwent the in
vivo pretreatment as in (3) above and 1 µM glutamate was added to the FIA buffer.
Figure 2.3. Glutamate electropolymerization events were captured on CFMs trimmed to
100 µm using a waveform with a wide potential window: −1.2 V to 1.3 V to −1.2 V at 400
V/ s. With FIA, data from 30 glutamate injections at 0.1 µM were collected followed by
10 injections each of 1, 20, and 100 µM. The peak at 1 V was quantified as the glutamate
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electropolymerization event, and the responses of four electrodes were averaged. Error bars
were calculated using standard error the mean.
Scanning Electron Microscopy (SEM). Electrodes were prepared for SEM imaging
by depositing PGA, employing two triangular waveforms: (1) −0.4 V to 1.3 V to −0.4 V
and (2) −0.4 V to 1.0 V to −0.4 V; each at 400 V/s. Electrodes were then transported to the
microscope in a closed container. The capillary glass was cracked, and the tip end of the
CFM was secured onto a stage with double-sided tape. SEM images were collected using
a Zeiss Ultraplus thermal field emission scanning electron microscope. Images in Figure
2.3Bi−iii were magnified on the Zeiss software, and the image in Figure 2.3Biv was
digitally magnified. The edge planes were imaged because significant electrochemistry
happens on this plane. The CFM modifications imaged are listed: 1. PBS, 1.3 V: CFMs
were cycled for 20 min total (60 Hz 10 min, 10 Hz 10 min) using triangular waveform 1,
with a positive potential limit of 1.3 V, in PBS. 2. Glutamate in PBS, 1.0 V: CFMs were
cycled for 20 min total (60 Hz 10 min, 10 Hz 10 min) using triangular waveform 2, with a
positive potential limit of 1.0 V, in 10 mM glutamate. 3. Glutamate in PBS, 1.3 V: CFMs
were cycled for 20 min total (60 Hz 10 min, 10 Hz 10 min) using triangular waveform 1,
with a positive potential limit of 1.3 V, in 10 mM glutamate. 4. In Vivo, 1.3 V: The electrode
was placed into the cortex of a rodent brain (AP: +0.8, ML: +1.7, DV: -0.5) and cycled for
approximately 20 min total (60 Hz 10 min, 10 Hz 10 min) with triangular waveform 1,
with a positive potential limit of up to 1.3 V.
Dopamine Analysis. 1 µM DA was measured using FIA either in the presence or
absence of 1 µM glutamate within the running buffer (1× PBS). CFMs were cycled for 20
min total (60 Hz 10 min, 10 Hz 10 min) prior to analysis, and the current response of four

22

CFMs was measured using the triangular waveform: −0.4 V to 1.0 V to −0.4 V at 400 V/s.
Cycling was then repeated immediately using a slightly modified triangular waveform:
−0.4 V to 1.3 V to −0.4 V at 400 V/s, and the current response of the same four electrodes
was reanalyzed. A t-test was used to determine statistical significance.
Atomic Force Microscopy (AFM). Electrodes were prepared for AFM imaging by
depositing PGA or Nafion on the day of analysis. Electrodes were transported to the AFM
in a closed container and mounted on a glass slide, with the electrode tip flat to the slide
surface. AFM images were collected using a Digital Instruments Dimension 3100 AFM
(Veeco Metrology Group) with a NanoScope IIIa Controller and a non-contact tip. In
Figure 2.3Ci−iii, CFMs were imaged immediately following pretreatment. Treatments
include (i) cycling a bare electrode in PBS buffer for 20 min (10 min 60 Hz, 10 min 10
Hz), (ii) electroplating Nafion (method described above), and (iii) electropolymerizing
PGA with triangular waveform (−0.4 V to 1.3 V to −0.4 V, scan rate of 400 V/s) by cycling
for 20 min (10 min 60 Hz, 10 min 10 Hz) in PBS buffer containing 1 µM glutamate. In
Figure 2.3Civ-v, CFMs were cycled (10 Hz) for 2 h with a triangular waveform (−0.4 V
to 1.3 V to −0.4 V, scan rate of 400 V/s) before imaging, to simulate the length of a typical
in

vivo

experiment.

Treatments

include

(iv)

Nafion

electroplating

and

(v)

electropolymerizing PGA on Nafion coated CFMs using the same procedure as (iii) prior
to cycling.
Figure 2.4. The “Jackson” waveform was employed to measure serotonin (0.2 V to −0.1
V to 1.0 V to 0.2 V, scan rate: 1000 V/s). In Figure 2.4A, 100 nM serotonin was measured
in the presence of 10 µM 5-HIAA in TRIS buffer on electrodes trimmed to 150 µm.
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Measurements were collected with FIA every 30 min for 2 h. The serotonin oxidation peak
at 0.7 V was quantified, and the current response of three or four electrodes was averaged.
Error bars were calculated using standard error of the mean. CFMs that underwent an
electrochemical activation pretreatment were cycled using a modified “Jackson” waveform
where the positive potential limit was raised to 1.3 V for 10 min at 60 Hz and 10 min at 10
Hz. The electrodes were then cycled again, and analysis was performed using the original
“Jackson” waveform (positive potential limit of 1.0 V). In Figure 2.4B, a CFM trimmed
to 150 µm was placed into the CA2 region of the mouse hippocampus (AP: −2.91 ML:
+3.35 DV: −2.5). Serotonin was evoked via electrical stimulation to the MFB (coordinates
above), and data was collected and average from four animals for the Jackson waveform
(black) and the same after a 10 min treatment period with the extended Jackson waveform
(yellow). The maximum amplitude of each current vs. time traces was recorded, averaged,
and reported in the inset bar graph. Error bars were calculated using standard error the
mean.

RESULTS AND DISCUSSION
Exposure to In Vivo Brain Environment Enhances Electrode Sensitivity.
The brain environment is rich in proteins, ligands, and many other redox-active
molecules that can interact with analytical probes. Such an interaction is thought to foul or
poison the surface. Carbon is generally hydrophobic and more resistant to the fouling
effects of biological agents than other common electrode materials.45,46 Nonetheless, the
carbon surface is altered when exposed to brain tissue. Detrimental interactions of
biomolecules with carbon can be particularly problematic for low concentration
measurements and/or analysis of rapidly fluctuating species, as is the case for in vivo
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analysis of serotonin neurotransmission. It is known that serotonin metabolites
electropolymerize on CFMs and reduce the CFMs’ sensitivity to serotonin.22,31 This is an
issue that we tackled in the past by pre-polymerizing a Nafion layer on the CFM under the
rationale that Nafion, a cation exchange polymer, would repel negatively charged serotonin
metabolites while preconcentrating serotonin cations.22 The modification enables
measurements of extremely low (approx. 10 nM) concentrations of evoked serotonin.22,28
While our laboratory routinely makes these measurements, serotonin FSCV has not
been adopted widely in the community because these signals are still very low. Thus, we
began this work by addressing the Nafion coating since several Nafion (and other polymer)
modification procedures have been updated since our first description.22,35,36,47 We began
by seeking to compare and contrast different CFM modification procedures in a bid to
improve FSCV sensitivity to serotonin. Since there is a general notion that the sensitivity
and/or response time of electrodes declines in vivo, as a starting point, we sought to confirm
the detrimental effects of the in vivo environment on CFMs. We focused this section of the
work on dopamine detection since the analysis of this molecule with FSCV is much better
understood than serotonin analysis. Four-point calibrations were performed on 16
electrodes (Figure 2.1A,B).
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Figure 2.1. CFM sensitivity pre- and post in vivo experiments. (A) Pre- and postcalibration data from an in vivo experiment measuring dopamine in the mouse nucleus
accumbens. (i) Representative in vivo FSCAV color plot and (ii) CVs in dopamine (500
nM), before (red), during (purple) and after (blue) in vivo measurements. (iii) Pre- (red)
and post-calibration (blue). Inset bar graph depicts the increase in the post-calibration slope
(p < 0.01). (B) Calibration data after an electrode was placed in the mouse dorsal striatum
and cycled with the dopamine waveform for 2 h. (i) Representative FSCV color plot and
(ii) CV in dopamine (500 nM) collected via FIA (above) along with the background signal
during pre-calibration and post-calibration (below). (iii) Pre- and post-calibration plot.
Inset bar graph depicts the increase in the post-calibration slope (p < 0.01). Error bars were
calculated using standard error of the mean.
In Figure 2.1A, eight electrodes were calibrated in TRIS buffer before implantation
into the nucleus accumbens of a mouse brain where extracellular dopamine was monitored
for 2 h with FSCAV. Representative color plots and CVs from these experiments are shown
in Figure 2.1Ai,ii, respectively. Interpretation of color plots can be found elsewhere;48
briefly, these plots convey current vs voltage collected at 10 Hz against collection time,
where current is given a false color. The calibration was repeated immediately following
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the in vivo experiment (calibrations are labeled PRECAL and POSTCAL in Figure
2.1Aiii). Contrary to the general view that the in vivo environment is detrimental to
electrode sensitivity, we found that the electrode sensitivity significantly increased post in
vivo implantation.
The slope of the calibration curve increased from 4.9 (±0.7) to 9.8 (±1.6) fC/nM (p
= 0.001, paired t-test). This effect persisted when FSCV was used in a different brain region
and calibrated in a different medium. In Figure 2.1B, CFMs were precalibrated, placed in
the dorsal striatum of a mouse brain for 2 h to measure evoked dopamine release, and recalibrated immediately thereafter in PBS. A representative color plot and CVs of the
Faradaic and background signals are shown in Figure 2.1Bi,ii. The background current
(mostly comprising capacitative current pre-background subtraction) substantially
increases post in vivo implantation; an effect that persists with electrodes that have been
electrochemically treated with glutamate only (Figure A.2 in supplemental), showing that
the surface chemistry of the electrode has changed. The pre- and post-calibration curves
are in Figure 2.1Biii. In agreement with FSCAV results, the slope increased significantly
in the post-calibration from 31.0 (±4.6) to 55.0 (±7.3) pA/nM (p = 0.004). These increases
in sensitivity were not seen when the electrodes were tested in their respective control
experiments in buffer alone (Figure A.1 in supplemental).
These results contradict the general status quo, which is that electrodes lose
sensitivity in vivo.36,49,50 However, a previous study displayed similar results,29 where the
current response to acetaminophen after in vivo measurements was larger than before the
experiment, and another where the response change to dopamine was insignificant.51 There
may be several factors to explain the contradiction such as experimental conditions, models
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and methods. Such differences may include electrode type (disk vs cylinder), waveform
(1.0 V vs 1.3 V potential limit), pretreatment before post-calibration (overnight soaking in
isopropyl alcohol vs no pretreatment post-calibration),49 time in vivo (several weeks),
which results in deterioration of the pseudo-Ag/AgCl reference electrode,52 and the time
after in vivo exposure and calibration (our calibration is immediately thereafter).
Nonetheless, in our hands this effect is significant and persistent. In sum, our results
suggest that an unidentified aspect of the in vivo environment contributes to a surface
alteration of carbon that improves the sensitivity of the electrode toward dopamine.
Analytical Response to Dopamine Is Improved with Glutamate Pretreatment.
When identifying potential biological molecules that might interact with carbon,
we identified glutamate, a neurotransmitter that is ubiquitous across brain regions. While
it is generally accepted that glutamate does not offer analytical electroactivity, glutamate
electropolymerization is well established in the literature with conventional, slow scan
cyclic voltammetry.40,42,53,54 In fact, electrochemical grafting of amines to carbon surfaces
is well demonstrated via a radicalinitiated C−N bond.55−57 Applying an electrochemical
potential not only drives bond formation between amine groups and carbon56,57 but also
facilitates electropolymerization of small amine-containing molecules like amino acids via
a chain-like growth mechanism.55 We thus hypothesized that, in vivo, the interaction of
glutamate with CFMs may create a polymer layer that facilitates the increase in sensitivity
observed in Figure 2.1. The rationale here is the structure of a potential PGA film,
possessing an overall negative charge, would enhance the preconcentration of cations.
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Figure 2.2 shows the first 3.5 s of a flow injection response of dopamine (1 µM)
onto CFMs. Bare electrodes (1) served as controls and response to the dopamine injection
was rapid, reaching the steady state (34.5 ± 3.8 nA) at 3.5 s (Figure 2.2A).

Figure 2.2. Analytical response of glutamate-treated and in vivo CFMs. FIA rise curves
of the first 3.5 s of a 1 µM DA injection on four different CFMs: bare (1), glutamate in FIA
buffer at 1 µM (2), in vivo (3), and in vivo + glutamate (4). Every third error bar is displayed.
(A) Bar graph of the FIA response to 1 µM DA on each pretreated CFM (*p < 0.05). (B)
Slope of the linear portion of the curve (0.4–1 s, R2 > 0.99).
Electrodes pre-treated (via electrochemical cycling) with glutamate (2) prior to and
during analysis at a concentration resembling ambient in vivo glutamate58 had a
significantly higher response than control (46.4 ± 4.8 nA, p = 0.05); the same held for
CFMs that had been in vivo (3) (45 ± 2.2 nA, p = 0.03). The highest current was from
electrodes that had been in vivo and were post-analyzed with glutamate in the FIA buffer
(50 ± 4.2 nA, p = 0.02). A similar, significant increase in sensitivity is seen with FSCAV
for electrodes before and after glutamate treatment.
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A concern with modified electrodes is whether a diffusional barrier might induce
temporal limitations in the response.22 We tested whether any of these scenarios slowed
down the FSCV response time via FIA in Figure 2.2B. In contrast to the expectation that
modifications slow the response, we found by estimating the slope of the linear portion of
the rise curve that all pre-treatments improved the speed of response ((3) 27.5 ± 0.4, (2)
31.6 ± 0.4, and (4) 34.6 ± 0.4 nA/s) with respect to the bare one ((1) 21.3 ± 0.3 nA/s).
Combined, these data show that carbon fibers that have been in vivo or have been pretreated
with glutamate display improved analytical response toward dopamine. We next explored
the interaction of the carbon surface with glutamate.
Glutamate Electropolymerizes onto CFMs with FSCV.
With conventional cyclic voltammetry, applying a high potential (>1.3 V) initiates
grafting of the glutamate monomer to carbon followed by chain growth of the polymer.39
Glutamate electropolymerization has not yet been explored with fast voltammetry; thus,
we asked, does glutamate electropolymerization occur at the fast scan rates employed with
FSCV?
We applied a waveform to the CFM with an intentionally wide potential window
(−1.2 V to 1.3 V to −1.2 V at 400 V/s) to best capture any polymerization peaks. Using
FIA, a rectangular pulse of glutamate (0.1 µM) was delivered to CFMs and the responses
were averaged. A representative color plot and CV are displayed in Figure 2.3Ai,ii where
the electropolymerization peak occurs at 1 V (denoted by the green arrow in Figure
2.3Aii). The first six injections in Figure 3Aiii reveal the polymerization peak, with an
average current response of 36.7 ± 2.9 nA. Successive injections show that this peak
diminishes over time (Figure 2.3Aii), decreasing to an average of 11.1 ± 1.0 nA or 30.2%
(p = 0.0002) of the original amplitude. The polymerization peak is indistinguishable from
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the switching peak (an artifact of the FSCV technique) by scan 30. Even when the
glutamate concentration was increased to 1, 20, and 100 µM, there was no significant
change in amplitude. We believe the disappearance of this peak is due to fewer available
sites for PGA attachment and chain length saturation. The structure of PGA on carbon is
depicted in Figure 2.3Aiv. In previous studies describing PGA electropolymerization with
conventional cyclic voltammetry, the free radical-initiated polymerization peak occurred
at around +1.5 V.39 Though the high potential is not within the potential window of our
FSCV waveform, we hypothesized that adsorption of glutamate to CFMs creates enough
thermodynamic favorability to initiate PGA formation. The polymerization peak at 1.0 V
suggests that this process is dependent on the application of a positive potential above 1.0
V. PGA formation on CFMs with a fast scan waveform that extends up to 1.3 V is an
interesting finding since the application of 1.3 V is known to increase sensitivity to DA.10
This effect has been attributed to overoxidation of the carbon surface, providing a fresh
surface for the next analysis and for creating oxygen moieties on the surface that preconcentrate the dopamine cation before analysis.10,11 Here, we suggest that 1.3 V also
facilitates the signal via PGA formation. Since electrochemical PGA formation onto the
carbon surface is covalent, the overoxidation process at 1.3V may be blocked at sites where
PGA has grafted to the CFM.
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Figure 2.3. PGA electropolymerization and coatings on CFMs. (A) Glutamate
electropolymerization at fast scan rates (i) Color plot from FIA injection of 0.1 µM
glutamate. (ii) Every fourth CV of 0.1 µM glutamate is displayed. (iii) Varying
concentrations (0.1, 1, 20, and 100 µM) of glutamate are measured by 60 successive
injections via FIA. Error bars: standard error of the mean. (iv) Molecular structure PGA.
(B) SEM images of CFMs: (i) bare, (ii) treated for 20 min (10 min 60 Hz, 10 min 10 Hz)
in [10 mM] glutamate using the triangular DA waveform (to 1.0 V), (iii) using the extended
dopamine waveform (to 1.3 V), and (iv) treated in brain tissue. (v) Bar graph comparing
the normalized current response of CFMs to 1 µM DA, cycled at 1.0 V and 1.3 V in PBS
and 1 µM glutamate. Statistics: t-test (**p < 0.01). (C) AFM images of CFMs modified by
(i) surface activation with extended dopamine waveform (cycled 10 min 60 Hz, 10 min 10
Hz in PBS), (ii) electrodeposited Nafion and (iii) PGA coated with the extended dopamine
waveform (10 min 60 Hz, 10 min 10 Hz in 1 µM glutamate). AFM images following
exposure to the extended dopamine waveform for 2 h modified with (iv) electroplated
Nafion and (v) Nafion with 1 µM glutamate added to the background buffer.

Given voltammetric evidence of film formation, film deposition was verified and
characterized via micro- and nanoimaging. PGA has been imaged on different carbon
surfaces including glassy carbon,40 carbon paste electrodes,59 carbon nanotubes,41,60,61
graphite,62 and reduced graphene oxide61,63 and other substrates such as Au nanoparticles;64
however, there have been no reports of PGA deposition on CFMs. Here, we imaged CFM
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surfaces with SEM. In particular, we were interested in observing the effects of waveform
limits (testing the importance of 1.3 V) on the CFM surface in the presence of glutamate.
In Figure 2.3Bi, the CFM was cycled in PBS with a 1.3 V positive limit. The carbon
surface appeared relatively smooth. In Figure 2.3Bii, the CFM was cycled in a glutamatecontaining buffer with a positive potential limit of 1.0 V; this waveform is not considered
to overoxidize the carbon surface.11,27,28 When treated in 1 µM glutamate, there were no
visible deposits on the CFM (data not shown). This is because SEM does not have the
resolving power to visualize the fine deposits of low glutamate concentrations (we
visualize these with AFM in Figure 2.3B below). With 10 mM glutamate, significant
deposits were visualized (Figure 2.3Bii). The large deposits indicate the presence of
polymers. In Figure 2.3Biii, the electrode was in a glutamate-containing buffer and the
positive potential limit of the waveform was increased to 1.3 V, a potential limit considered
to etch the carbon surface. These electrodes appear to have a thinner deposition layer than
the 1.0 V waveform (Figure 2.3Bii). In Figure 2.3Biv, the electrode was cycled in vivo for
20 minutes. There is a visible film on the electrode surface; such deposits have been
previously seen after in vivo implantation, attributed to debris and biomaterials.36,65
The bar chart in Figure 2.3Bv compares the response to 1 µM dopamine before and
after CFM treatment in 1 µM glutamate between the 1.0 and 1.3 V upper limit dopamine
waveforms. In combination with the SEM images collected, the thinner apparent film
corresponds to higher sensitivity to dopamine. This implies that having a positive limit of
1.0 V encourages a thicker layer of PGA, potentially creating a kinetic barrier. In contrast,
the application of 1.3 V simultaneously etches the carbon as the polymer is deposited, such
that the polymer is thin enough to act as a pre-concentration matrix and not as a barrier.
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AFM is a useful tool for studying the morphology of conductive coatings on
electrodes and could provide insights into how PGA is formed on electrodes in vivo. We
compared different PGA deposition paradigms to Nafion (abbreviated to NA in Figure 2.3
and further figures) electrodeposition, which we have previously characterized in
detail.21−25,28 In Figure 2.3Ci, the distinct carbon striations are apparent on a bare CFM.
After deposition of Nafion (Figure 2.3Cii) or PGA (Figure 2.3Ciii), the natural carbon
striations are shallower and the surface is significantly roughened, as seen
previously.40,63,66,67 Other reports of PGA morphology with AFM on glassy carbon and
reduced graphene oxide display similar surface features, however the PGA deposition was
more homogeneous than we find.40,63 When comparing the Nafion coating to the PGA
coating, differences in morphology are clear. NA is uniformly deposited while PGA is
deposited more sparsely with large patches of the surface devoid of the polymer. This is
likely due to the inherent mechanistic differences between Nafion and PGA deposition:
Nafion is electrostatically plated while PGA is polymerized from the monomer by
covalently grafting to active sites on the carbon surface. In Figure 2.3Civ, theNafioncoated electrode was imaged after 2 hrs of electrochemical cycling and it is seen that the
coating is degraded with time. Nafion-coated electrodes are commonly employed for
biological analysis, and it has been thought that the Nafion-coating enhances the signal
stability throughout an in vivo experiment,22,32,35 a phenomenon difficult to reconcile with
our finding here. Because at 1.3 V, the underlying carbon is etched away, a large portion
of Nafion is removed; thus, it is interesting that Nafion-CFMs are still effective for in vivo
experiments over several hours. This experiment, however, does not reflect the in vivo
environment where there is a persistent, innate high concentration of glutamate. Thus, to
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better reflect the in vivo matrix, an Nafioncoated CFM was cycled for 2 hrs in the presence
of ambient glutamate (Figure 2.3Cv). The deposits on this electrode appear more
substantial. Of particular interest is the feature denoted by the blue arrow. Here, there
appears to be heavy deposition along the vector of a single striation. This behavior implies
that Nafion deposition is sparse within these ridges, leaving binding sites available for PGA
initiation and that the deeper sections of carbon’s striations are a more favorable surface
for PGA deposition. We postulate that this is because there are more ridges or imperfection
sites where the polymer can nucleate and grow. Nucleation and growth processes are
dependent on surface imperfections and are described in great detail for metals.68−70 This
finding is not surprising since radicalinitiated polymers are formed via chain growth (vide
supra).71−74 From this data, we suggest in vivo that PGA codeposits on electrodes
pretreated with Nafion, stabilizing, or even replacing the Nafion throughout an experiment.
PGA Facilitates Serotonin Detection.
The investigations above with dopamine determined that PGA formation on carbon
fibers increases electrode sensitivity and stability. We now asked whether these effects are
maintained for serotonin. FSCV serotonin detection is fundamentally more challenging
because of low evocable serotonin concentrations and high ambient concentrations of 5HIAA; this metabolite also polymerizes on the electrode but serves to degrade the electrode
sensitivity.22,29−31 This is illustrated in Figure 4A
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Figure 2.4. Serotonin responses with surface modifications with FIA and in vivo. (A)
Time of exposure to 10 µM 5-HIAA (every 30 min for 2 h) vs current response (nA) is
plotted of 100 nM serotonin, and surface modifications are compared: Bare (red, n = 3),
NA (blue, n = 4), and Nafion-coated carbon fiber activation via exposure to an
overoxidizing waveform (positive potential limit of 1.3 V, green n = 3) and PGA (yellow,
n = 4). (i) Bar graphs of current response at initial (0 min) and final time point (120 min).
(B) Current vs time traces of serotonin collected in vivo are averaged (n = 4) and compared:
extended Jackson waveform pretreatment (yellow) vs. the Jackson waveform on NA
electrodes (gray). Inset: bar graphs comparing the average amplitude of each treatment.
Representative in vivo color plot and CV are shown below, where the oxidation and
reduction peaks occur at 0.7 and 0 V, respectively. Statistics: t-test with respect to the bare
electrode (**p < 0.01, *p < 0.05).
where bare electrodes (red markers) are utilized to measure serotonin (100 nM) with the
standard Jackson waveform75 giving a response of 7.4 ± 0.9 (red bar in the inset bar graph).
When this electrode is cycled in a buffer containing 5-HIAA (5 µM), repeated injections
of serotonin result in a significant loss of signals (1.3 ± 0.4 nA). While the initial response
is greatly improved with Nafion modification (blue markers and blue bar in the bar graph)
(16.8 ± 1.2 nA, p = 0.001 compared to bare), after 120 min of repeated serotonin injections
in 5-HIAA, the signal is significantly diminished (2.7 ± 0.4 nA, p = 0.03). This is consistent
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with the AFM study above that showed severe degradation to the Nafion layer with
waveform application. The electrode response and stability can be substantially improved
with the application of a pretreatment step whereby the Nafion-coated electrode is cycled
in glutamate containing buffer with a 1.3 V upper limit on the Jackson waveform and then
analyzed in a buffer that contains both 5-HIAA and glutamate with the 1.0 V waveform
(yellow markers and trace; initial: 19.5 ± 4.6 nA, p = 0.04; final 6.4 ± 1.2 nA, p = 0.01).
These results are consistent with our hypothesis above that glutamate serves to stabilize or
replace Nafion when 1.3 V is applied. To show that this improvement in response is not a
simple consequence of the 1.3 V upper limit creating more adsorption sites, the green
markers and trace show that Nafion electrodes at cycled at 1.3 V without glutamate
pretreatment or glutamate in the buffer do not have a significant effect on the response at
the end of the experiment (initial: 12.6 ± 0.3 nA, p = 0.003; final 2.8 ± 1.3 nA, p = ns).
We thus followed the PGA paradigm to complete an in vivo experiment to test
whether pretreating a Nafion electrode at 1.3 V in the brain would serve to increase
sensitivity using the rationale that glutamate (and/or similar amino acids) facilitates the
response. In Figure 2.4B, we measured serotonin in the CA2 region of the hippocampus
of four mice with the Jackson waveform using a Nafion-coated electrode (black). Serotonin
concentrations increase upon stimulation of the serotonin axons (denoted by the yellow bar
under trace) and then clear rapidly after stimulation. We implemented an in vivo activation
step (extending the Jackson waveform to a 1.3 V positive potential limit for 10 min at 60
Hz, 10 min at 10 Hz). The original Jackson waveform was restored for measurements. We
observed a >2-fold increase in response as seen by the evoked release event (yellow; 0.79
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± 0.08 nA to 1.84 ± 0.11 nA, p = 6 × 10−5 ). A color plot and CV of this event (below)
show the relative high integrity of the signal.
We do not believe that glutamate is the sole player here given the abundance of
structurally analogous molecules in the brain (aspartate and lysine among others76−78).
More likely, glutamate is part of an intricate network of molecules that polymerize in
complex ways onto carbon and serve to draw equilibria that facilitate and impede the
electrode’s response. While we have long known about the detrimental effects of these
molecules (such as 5-HIAA), here, we provide new evidence that glutamate’s interactions
with carbon are beneficial for dopamine and, importantly, serotonin detection, which was
the initial aim of this project.

CONCLUSIONS
Carbon has been used for decades for biological analyses and is particularly
applicable to neurotransmitter analysis in the CFM form. Much of the work with CFMs
has been on dopamine detection, but our interests lie in improving serotonin detection at
CFMs. We began this work by investigating the carbon surface under the assumption that
exposure to the in vivo environment is detrimental to electrode sensitivity. In contrast to
this assumption, we found that electrodes that had been exposed to the in vivo environment
for up to 2 h were more sensitive to evoked and ambient dopamine. We postulated that
high concentrations of innate glutamate in vivo serve to polymerize with a negative charge
on CFMs and facilitate response to dopamine. We verified this polymerization
electrochemically and characterized the mechanisms of deposition. Critically, we
identified that the application of 1.3 V as an upper waveform limit is a key factor for
increasing electrode sensitivity to dopamine and experimental stability by augmenting
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Nafion film integrity. Finally, we applied the knowledge gained from these dopamine data
sets to an in vivo serotonin experiment where we were able to induce a 2-fold increase in
response to serotonin. We present not only the novel finding that innate aspects of the in
vivo environment are auspicious for dopamine and serotonin detection via carbon, but also
offer an improved FSCV serotonin detection paradigm.
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Chapter 3: Novel, User-Friendly Experimental and Analysis
Strategies for Fast Voltammetry: 2. Next Generation FSCAV
Serotonin Measurement and Analysis1
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ABSTRACT
Fast voltammetry is an attractive technique to measure neurochemicals in the brain. This
technique is biocompatible, causes minimal tissue damage and has real-time temporal
resolution. Fast voltammetric techniques have been adapted to measure the ambient or
tonic state of neurotransmission (Fast-Scan Controlled Adsorption Voltammetry
(FSCAV)) for both serotonin and dopamine. This method is advantageous because of the
important biological information in the ambient levels of neurotransmitters: serotonin in
the case of our studies. The key to better understanding and treating the disorders in
which this modulator is implicated is to decipher the mechanisms that control the tonic
extracellular serotonin levels. Since the advent of FSCAV, our lab has developed and
employed this niche tool to probe and understand native and pharmacological effects on
the serotonin system in mouse models, giving great insight into the role of serotonin in
depression. However, some limitations regarding the stability of signals over prolonged
periods needs to be evaluated and addressed. Here, we show a robust analytical method to
improve the stability of electrodes both in vitro and in vivo. We reduce FSCAV electrode
drift by electrochemically polymerizing amino acids onto the surface of the carbon fiber.
This work is intended to provide the research community with improved analytical
capabilities of carbon fiber microelectrodes to measure tonic serotonin concentrations in
biological environments.

INTRODUCTION
Serotonin plays important roles in brain physiology and disease. Fast-scan cyclic
voltammetry (FSCV) can probe in vitro and in vivo serotonin dynamics at carbon fiber
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microelectrodes (CFMs).1-10 FSCV is only capable of measuring evoked or phasic changes
in analytes because it is a background subtracted method. Background subtraction is
required to remove a large non-Faradaic charging current consequent with high scan rates
(hundreds to thousands of volts per second).10, 11 While this information has critically
advanced the understanding of serotonin in the brain, basal or ambient level serotonin
measurements are also critical. There are a number of ways to study ambient analyte levels
in the brain such as microdialysis,12,

13

multiple-cyclic square wave voltammetry

(MCSWV)14 and fast scan controlled adsorption voltammetry (FSCAV).7
We have employed FSCAV for ambient serotonin measurements in a variety of
studies. We have investigated differences in ambient serotonin in response to
antidepressant administration in male vs. female mice,8, how small differences in regional
extracellular serotonin concentration are informative of local tissue architecture15 and
recently we showed rapid modulation of brain serotonin in response to bodily
inflammation.16
We have encountered an experimental challenge with FSCAV, which is analyzed
via integration of the Faradaic peak. The issue is a long (average 1.5 hrs) equilibration
period after the FSCAV paradigm is applied in vivo, which significantly extends
experimental time. In this work, we tackle matrix issues to significantly reduce
experimental time and improve the ease and reproducibility of FSCAV serotonin analysis.
By making use of a newly developed understanding of how the in vivo chemical
environment interacts with carbon fibers in an auspicious way to improve stability and
sensitivity,17 we are able to dramatically decrease in vivo electrode equilibration time. We
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thus present new experimental approaches to facilitate efficient and robust serotonin
FSCAV data acquisition.
EXPERIMENTAL
Chemicals and Reagents
Mice were anesthetized using urethane. Electrodes were treated with Gamma-aminobutyric
Acid (GABA) (2.5 µM), Glycine (Gly) (34 µM), Glutamate (Glu) (21.3 µM), Tyrosine
(Tyr) (7.2 µM), Tryptophan (Trp) (11.1 µM), Cysteine (Cys) (1.12 µM), Lysine (Lys) (26
µM), and/or Aspartate (Asp) (0.2 µM) individually or as a combination as dictated above
in the manuscript. These Amino Acids (AAs) were dissolved into a 1x phosphate buffered
saline (PBS) that was diluted from a 10x premixed buffer. All chemicals were purchased
from Sigma Aldrich (St. Louis, MO, USA).

Flow Injection Analysis (FIA)
FIA was performed in a system custom-built in-house. CFMs were inserted into flangeless
short 1/8 nuts (PEEK P-335, IDEX, Middleboro, MA, USA), exposing a small portion of
the tip (2 mm) outside of the nut. An HPLC union (Elbow PEEK 3432, IDEX, Middleboro,
MA, USA) was modified such that the nut containing the microelectrode was fastened to
one end. The out-flowing stream of the FIA buffer was fastened to the other end of the
elbow union. Two holes were drilled into the union for the incorporation of the pseudoAg/AgCl reference electrode and the “waste” flow stream. A syringe infusion pump (KD
Scientific, Model KDS-410, Holliston, MA, USA) was used to maintain the flow at 2 mL
min −1. The analyte was introduced into the flow stream for 10 s via a six-port HPLC loop
injector (Cheminert Valve, VICI, Houston, TX, USA) as a rectangular plug.
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Animals and Surgical Procedure
Mice (C57BL/6J) (Jackson Laboratory, Bar Harbor, ME, USA) were injected with a 25%
urethane solution based on a calculation that is dependent on their weight (7 µL/g).
Following anesthetic administration, the mouse was placed into a stereotaxic system
(David Kopf Instruments, Tujunga, CA, USA) where body temperature was maintained
via heating pad (Braintree Scientific, Braintree, MA, USA) Three holes were drilled into
the skull of the mouse based on coordinates from the mouse brain atlas. The working
electrode was placed in the CA2 region of the hippocampus (CA2: -2.91, +3.35, -2.50) the
stimulating electrode (insulated stainless-steel, diameter 0.2 mm, untwisted, Plastics One,
Roanoke, VA, USA) was placed in the medial forebrain bundle (MFB: -1.58, +1.00, -4.80),
and the pseudo-Ag|AgCl reference electrode was placed in the opposite hemisphere of the
brain as the working and stimulating electrodes. Animal use followed NIH guidelines and
complied with the University of South Carolina Institutional Animal Care and Use
Committee under an approved protocol.

Microelectrodes Fabrication
Carbon Fiber Microelectrodes (CFMs) were made individually by aspirating a single
carbon fiber (Goodfellow Corporation, PA, USA) into a 0.6 mm x 0.4 mm glass capillary
(A-M Systems, Inc., Sequim, WA, USA). The capillary was then pulled by a vertical puller
(Narishige, Tokyo, Japan) to create a carbon-glass seal. The carbon fiber was then trimmed
to 150 ± 5 𝜇m for serotonin electrodes. Liquion (LQ-1105, 5% by weight NafionTM) (New
Castle, DE, USA) was electrodeposited onto the surface of the carbon fiber by dipping and
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applying a constant potential of +1.0 V for 30 s. The electrode was then dried at 70 °C for
10 minutes and used after 24 hours.
Hardware
FSCAV was performed using a Dagan Potentiostat, (Dagan Corporation, Minneapolis,
MN, USA), National Instruments multifunction device USB-6341 (National Instruments,
Austin, TX, USA), WCCV 4.0 software (Knowmad Technologies LLC, Tucson, AZ, USA)
and a Pine Research headstage (Pine Research Instrumentation, Durham, NC, USA). Data
filtering (zero phase, Butterworth, 2 kHz low-pass) and signal smoothing were done within
the WCCV software.
Data Collection
FSCV
A selective waveform for serotonin was applied to the electrode (Serotonin: +0.2 V to +1.0
V to -0.1 V to +0.2 V, 1000 V s-1) at the frequency of 10 Hz. The output of this technique
was a colorplot generated using custom software. From this, a cyclic voltammogram was
collected every 100 ms with a signature serotonin redox peak that appears at 0.7 V. A
current vs. time plot was also extrapolated from this color plot showing the change in
serotonin concentration over time. Current vs time will then be turned into concentration
vs. time by using a predetermined calibration factor. This method is a background
subtracted method due to the very fast scan rate generating a large nonfaradaic current. A
change must be induced to visualize serotonin’s redox processes: this is accomplished in
vivo via electrical stimulation.

FSCAV
FSCAV was performed in three steps: (1) the serotonin waveform was applied at 100 Hz
to minimize adsorption of serotonin to the electrode surface; (2) a fixed potential (0.2 V)
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was applied for 10 s, allowing for maximized adsorption; (3) the waveform was then
reapplied and the first signature cyclic voltammogram collected was used to measure
ambient serotonin concentration. The concentration was found via a post-calibration
process (vide infra). An electronic relay was employed to switch between the serotonin
specific waveform described above and a constant potential for a controlled adsorption
period.
Computational Methods
FSCAV Measurement Methods
Limits of integration to estimate the charge of the faradaic peak and maximum amplitude
from FSCAV serotonin cyclic voltammograms are obtained using custom-designed
automatic local minima and local maxima algorithms implemented in The Analysis Kid.18
Charge of the faradaic peak is calculated using the Simpson’s rule. The first integration
point is normalized to have a current value of zero to avoid subtraction of area between the
negative and positive currents of the CVs. A linear regression is obtained between the two
integration points to obtain the baseline used to measure the faradaic charge. This
minimizes the interference from the capacitive peak. Linear regression models from
postcalibrations are obtained using linear least squares between concentration labels and
estimated charge of the serotonin faradaic peak. The coefficient of determination (R2) and
the standard error of the estimate are used as parameters to assess the goodness of
fit. FSCAV experimental drifts (vide infra) are modeled with a shifted negative exponential
function shown in eq.1
Q(t) = - Q0 e-kt+ Qf

(1)

where Q(t) is the charge of the faradaic serotonin peak at time t, Q0 and Qf determine the
position of the exponential function in the Cartesian axes, and k is the exponential constant
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that determines the speed of growth. The time constant of the exponential function, t63%
= 1/k, is used to characterize the speed of the sensor to achieve stability. The sensor
response time (this was defined as the time it takes the sensor to reach 95% stability), was
set as three times the time constant, since t95% ≈ 3t63%. The nonlinear fitting is performed
using the Levenberg-Marquardt algorithm.19 Subtraction of the exponential fit is performed
by adding to the experimental trace an exponential decay function (Q0 e-kt) with the fitted
parameters.
Statistical Analyses
Statistical significance is defined as p < 0.05. All statistical tests are performed using
Python 3.6 SciPy library20 and Matlab 2020b. Distribution of samples are shown as mean
± SEM if not stated otherwise. Error of model predictions is shown as the RMSE between
true and predicted concentrations. FSCAV post-calibrations and in vivo predictions of
serotonin were tested for significance using analysis of variance (ANOVA) and TukeyKramer post-hoc multiple comparisons. See the Supplementary Information for a full
description of the statistical analyses.
RESULTS AND DISCUSSION
A New Technique to Improve FSCAV Equilibration Time
As with most in vivo methods, electrochemical methods for in vivo analysis can be
characterized by an equilibration time. We define this equilibration time for FSCAV as the
time it takes for the electrode surface to come to 63% of equilibrium in the complex system.
This equilibration time is in part due to the high acquisition rate of the technique as well as
the scan rate/frequency at which the waveform is applied, but mostly it is dependent on the
environmental matrix itself: e.g. protein redox behavior, biofouling, etc.21-25 During this
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time, the electrode itself has not consistently met a steady state, thereby making these
electrochemical measurements unreliable. It is essential to reach a steady state before
beginning experimental analysis.
Specifically, with FSCAV data analysis has a baseline drift associated with the
equilibrium has been found to be challenging. In Figure 3.1, representative examples of
this drift are given for in vitro and in vivo recordings. The in vitro trace in panel A was
obtained by measuring the electrode response to 75 nM serotonin in PBS for 120 minutes.
This in vitro signal decays over time and reaches steady state after about 30 minutes. It can
be modeled with the shifted negative exponential function shown in eq.1, which allows us
to obtain an estimation of the response time of the electrode. We hypothesized that this
drift is a direct result of stripping of the Nafion layer from the electrode surface in vitro,
which is supported in Chapter 2 where we showed that the Nafion layer is unstable in a
beaker (but not in vivo).
The in vivo trace in Figure 3.1 panel B was obtained by measuring the electrode
response to serotonin in the CA2 region of a mouse hippocampus for 120 minutes. The
highlight feature of this in vivo drift is that the baseline shows a logarithmic growth rather
than the decay seen in the in vitro signal.
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Figure 3.1: In vitro and in vivo representative examples of FSCAV acquisition for 120
min. (A) In vitro FSCAV acquisition in PBS-buffered 75 nM serotonin solution. From the
fitted curve mode, the time constant is estimated to be 9.16 min. (B) In vivo FSCAV
acquisition from the CA2 region of a mouse hippocampus. From the fitted curve model,
the time constant is estimated to be 43.93 min. Part A and Part B show similar trends and
comparable stability times. Interlaid in red, the experimental data is shown for both
acquisitions after the exponential model subtraction (vide supra)
The drift in each case must be derived from different sources. Presently the
exponential trace model can be used to eliminate the excess time for stability to be reached
by subtracting the drift from the experimental trace. Figure 3.1 shows this in practice on
the in vivo and in vitro examples of the experimental traces together with the exponential
model fit and the experimental trace after subtraction (see red). This estimation of the drift
takes place on the section of the trace where we assume that the drift estimation is not
influenced by evoked physiological changes, which would undermine the drift subtraction
process. To remove this assumption, it is better to wait until the electrode has reached
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equilibrium; however, such a long wait period (over 2 hrs) may come at the expense of
experiment failure (i.e. animal death). We thus ask 2 questions here: 1) what causes the in
vivo drift and 2) how do we improve equilibration time?
In Chapter 217, we showed that after in vivo implantation of the CFM there was a
robust increase in sensitivity toward serotonin and dopamine. One contributing factor to
this finding is high extracellular glutamate levels resulting in polyglutamate
electropolymerization on the electrode surface facilitating the preconcentration of
serotonin and dopamine.17, 26 In this work, such a layer may also stabilize the Nafion
coating in vivo and eliminate the exponential decay drift observed in vivo in Figure 3.1.
However, polyglutamate may not be the only contributor to this phenomenon. We
hypothesized that other amino acids in the in vivo environment may be contributing to the
formation of complex polymer layers on the electrode surface, taking over 120 minutes to
reach an equilibrated state and serving to increase electrode sensitivity. Here, we
investigated a variety of amino acid pretreatments and their effects on equilibration time.
We first set out to determine which AAs contribute to a robust change in sensitivity
toward serotonin via flow injection analysis using FSCV in Figure 3.2. Using FIA, the
initial electrode response to 1 µM serotonin was recorded in PBS buffer. Then, the
electrode was modified to polymerize one of eight AAs chosen based off of their similarity
in size and charge to glutamate, abundance in the CA2 region of the hippocampus or
involvement in serotonin and DA synthesis pathways.27-32 To polymerize the AAs onto the
CFM surface, the following steps were employed: 1) the electrode was placed in
biologically relevant concentration of the specific AA in a PBS matrix. 2) we the applied
a wide potential window, as previously noted in chapter 2, from -1.2 V to 1.3 V to -1.2 V
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for 10 mins at 60 Hz. 3) the electrodes were then cycled on the serotonin waveform in PBS
at 60 Hz for 10 mins and 10 Hz for 10 mins. Then, the electrode response to 1 µM serotonin
in PBS buffer was recorded again and sensitivity shifts were attributed to the AA
modification. In Figure 3.2, it was determined from this experiment that Cys (blue), Glu
(purple), Gly (violet), and GABA (pink) electrode modifications (students t-test, p < 0.005)
are major contributors to sensitivity shifts toward serotonin using FSCV. Each contributes
to a ~ 50% change in sensitivity toward serotonin compared to control waveform
experiments (brown).

Figure 3.2: Surface Modifications Towards Serotonin Sensitivity. All electrodes in this
data set are Nafioned. The polymer waveform (-1.2 V to 1.3 V to -1.2 V) was applied and
each AA modification was compared to this control (brown). Of the 8 AAs studied, Cys,
Gly, Glut and GABA were shown to have the significant effects on sensitivity compared
to control. Response and error bars show the mean ± SEM across 5 electrodes.

Next, we set out to determine whether these four AAs affected the FSCAV signal
in Figure 3.3. Using FSCAV, the electrode response to 75 nM serotonin in PBS buffer
was recorded over a period of 60 minutes. Then, the same electrode was modified (see
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Figure 3.2 description for methods) with one of the four AAs. Then, the electrode response
to 75 nM serotonin in PBS buffer was recorded for another 60 minutes, and significant
sensitivity shifts were determined to be a result of AA electrode modification. From this
experiment, it was determined that glycine, glutamate, and GABA (p < 0.01) electrode
modifications are major contributors to robust sensitivity shifts toward serotonin using
FSCAV. Of note, there was no effect of applying the polymerization waveform in the
absence of AA (one-way ANOVA, F = 1.1650, p = 0.3558) (see Supporting Information).
Next, we concentrated on the effect of these three AAs in a matrix more
complicated than PBS (comprising all 8 amino acids, to better mimic the brain) and found
the same trends. In Figure 3.3, electrodes modified with AAs appeared to reach a point of
stability at a quicker rate than simply Nafioned electrodes in this matrix. Thus, a time
constant (t63%) was calculated in addition to the sensitivity (pC/𝜇M) and both were plotted
in panel B. It was observed that modification with glutamate, glycine, and a combination
of glutamate, glycine, and GABA resulted in a significant decrease in time to stability
compared to no polymerization (one-way ANOVA and post-hoc test on the 𝑡#$%
differences pre and post polymerization, glutamate: ∆𝑡#$% = 34.49 ± 4.07 min vs. -16.75 ±
3.76 min, p = 0.0005; Glycine: ∆𝑡#$% = 27.02 ± 13.24 min vs. -16.75 ± 3.76 min, p =
0.0028; 3 AAs: ∆𝑡#$% = 28.46 ± 6.26 min vs. -16.75 ± 3.76 min, p = 0.0021). GABA
polymerization alone decreases the time constant, but this decrease is not significant
(GABA: ∆𝑡#$% = 12.48 ± 3.14 min vs. -16.75 ± 3.76 min, p = 0.0636). However, the
sensitivity of the electrode does increase (N.S.) after the application of the extended
waveform. This is most likely due to the etching of the CFM surface and the additional
oxygen moieties that would be formed on the electrodes surface at this high potential.33
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Figure 3.3: FSVAV Beaker Matrix Effects. (A, B, C, D) In vitro FSCAV acquisitions in
AA-PBS-buffered 75 nM serotonin solution together with the polymerization of the amino
acid stated in the graph of each panel. Scatter points and error bars show the mean ± SEM
across 5 electrodes. The gray bar shows the time at which the polymerization waveform is
applied. (E) In vitro FSCAV acquisitions in PBS-buffered 75 nM serotonin solution with
Nafion only. Scatter points and error bars show the mean ± SEM across 5 electrodes. The
gray bar shows the time at which the polymerization waveform is applied.

Based on the results from the in vitro studies above, a series of experiments were
performed in order to even better subside the baseline drift while utilizing this new polymer
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coating (see Supporting Information Figure B.2). In brief, the combination of AA
modifications determined in Figure 3.3 was investigated with various time periods of
holding at 0.2 V, the holding potential of the Jackson waveform. It was found that the
combination of modification with the three AAs and holding at 0.2 V for 10 min best
alleviated the baseline drift. This new analysis paradigm was finally employed in vivo in
Figure 3.4.
Figure 3.4, shows Nafioned electrodes (red, n = 8), the standard pretreatment for
our electrodes for in vivo analysis, in the CA2 region of the hippocampus measuring
ambient serotonin. The normalized baseline drift again was fit to determine the t63%, which
was found to be 38.84 ± 5.85 min. This was directly compared to the proposed GABA,
glutamate and glycine modified electrode. This was then compared to that of the proposed
analysis paradigm of the three AA combination electrode modification and holding at 0.2
V for 10 minutes (blue, n = 5). These experimental traces were fit to estimate a t63% = 20.22
± 3.04 min. As evident in Figure 3.4A, AA polymer electrodes have a faster response time
compared to electrodes treated only with Nafion polymer (Figure 3.4B, Student’s t-test, p
= 0.0376).
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Figure 3.4: Surface treatments of the carbon fiber with polymerized amino acids. (A)
Mean ± SEM (n = 5 electrodes) of sensitivity at the end of the experiment and time constant
of the drift model. Statistical significance (p < 0.05) of the differences is shown with an
asterisk (one-way ANOVA and post-hoc test of differences in sensitivity and time constant
pre and post polymerization). For each treatment, the left bar shows the statistics measured
pre polymerization, while the right bar corresponds to the same parameters measured post
polymerization. (B) Mean ± SEM in vivo traces of the Nafion-only electrode acquisitions
(red, n = 8 animals) and AA-polymerized electrodes (blue, n = 5 animals). AA
polymerization was performed by the application of the extended polymer waveform (-1.2
V to 1.3 V to -1.2 V) prior to data acquisition. (C) Mean ± SEM of drift time constant for
both datasets. The drift model was fit to each of the experimental traces. Nafion electrodes
in the in vivo matrix, take a longer stability time compared to Nafion/AA treated electrodes
(Student’s unpaired t-test t63% = 38.84 ± 5.85 min vs. 20.25 ± 3.04 min, p = 0.0376).
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CONCLUSIONS
FSCAV has given great insights in the study of serotonin tonic concentrations in
vivo, but despite these achievements, some challenges regarding the calibration and
stability of signals had to be addressed. In this work, we have shown robust methods to
correct and improve the stability of electrodes and the prediction capabilities of FSCAV
calibration models. First, we have shown a method to mathematically correct electrode
drift FSCAV experiments. After that, we developed an experimental approach to minimize
the FSCAV electrode drift taking advantage of the complexation of AAs to carbon
surfaces. The novel treatment of the CFM surface, which included the electrodeposition of
Nafion and 3 AAs (glycine, GABA and glutamate) has been shown to be advantageous
both in vitro and in vivo. We believe that this work will make serotonin ambient detection
more user-friendly and accessible to other research groups.

56

Chapter 4: Voltammetric Assessment of the Effects of
Different Antidepressant Types on In Vivo Serotonin1

1

Witt, C. E., Mena, S., Berger, S. N., Parke, B., Hersey, M., Ou, Y., Honan, L. E., Fadel,
J. and Hashemi, P. Voltammetric Assessment of the Effects of Different Antidepressants
Types on In Vivo Serotonin. In Preparation. Cells.
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ABSTRACT
Depression is the leading cause of disability in the world, yet this disorder is notoriously
difficult to treat. Over the last few decades there have been several classes of antidepressant
therapies that have precipitated from different theories outlining mechanisms of depression
However, because the neurochemical underpinnings of depression are not well defined,
these therapies suffer poor efficacy rates and new therapies are difficult to develop. In this
chapter, we outline the application of fast scanning electrochemical techniques to directly
detect serotonin dynamics in response to several classes of antidepressants. We review the
major classes of antidepressants and assess their effects, utilizing novel analytical tools, on
serotonin dynamics in the brain to correlate this chemistry to clinical efficacy. Thus, we
highlight the critical role for electrochemical techniques in the assessment of current
antidepressants and the development of new pharmacological treatments.
INTRODUCTION
Neuropsychiatric diseases, like depression, affect an already large and growing
number of individuals. Depression in now classified as the primary contributor to the global
burden of disease.1 This is due, in large, to the currently limited understanding of this
debilitating disease. Though years of research have gone into understanding the pathology
of depression, there are still more questions than there are answers. Clinically, patients
have been treated with an array of pharmaceutical agents all classified under the umbrella
of “antidepressants”. Antidepressants (ADs) are classified into groups based on time of
discovery, mechanism of action and pharmacological targets.2, 3 Key AD groups include
tricyclic amines (TCAs), monoamine oxidase inhibitors (MAOIs), selective serotonin
reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors (NRIs) and modern/novel
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ADs (including ketamine). Unfortunately, the reason so many ADs and so many classes
of ADs are available on the market is that most ADs have low efficacy4, 5 and a delay of
therapeutic effects that greatly mar their ability to act to improve depression symptoms6, 7,
per their intended use. Importantly, improving the efficacy of ADs has been the focus of
pharmaceutical companies for decades and thus many new ADs have emerged on the
market. These ADs’ mode of action ranges from the glutamatergic system all the way to
primarily acting on serotonin, dopamine or norepinephrine respectively. All have shown
varying clinical efficacies, however, there are no screening tools for these drugs.
Screening and analysis techniques for ADs are essential to improving drug
discovery. Researchers have employed microdialysis, electrophysiology and PET imaging
to probe depression neurochemistry and screen ADs.
understanding

pharmacological

dynamics

in

vivo

The golden standard for
has

been

microdialysis.

Microdialysis can quantitatively analyze the direct and downstream effects of each AD to
increase extracellular serotonin following acute/chronic administration limited only by its
temporal resolution and large probe size.10, 11 For example, David et al. showed a dose
response and potency/efficacy analysis of serotonin efflux with the SSRIs paroxetine,
citalopram, and venlafaxine.12 Electrophysiology overcomes the large probe size and
minimal temporal resolution; however, it is limited to the measurement of the electrical
activity of single neurons. Czachura et al. employed electrophysiology study doses, and
routes of administration of the SSRI fluoxetine on firing activity of serotonergic neurons
in the dorsal raphe nucleus.13 PET imaging is minimally invasive and can be used to
determine receptor or transporter populations, however, it is not capable of
determining neurotransmitter concentrations. Riad et al. determined that fluoxetine
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administration resulted in increased internalization of 5HT1A autoreceptors in the dorsal
raphe nucleus using PET studies. This autoreceptor internalization is predicted to be
essential to SSRI/fluoxetine efficacy.14 These analytical techniques have separately made
great strides in characterizing antidepressant mechanisms’.
Analytical chemistry provides a unique opportunity to improve screening and
analysis techniques for ADs. We present how fast electrochemical techniques can also be
used as a screening tool and for novel analysis. Fast-scan cyclic voltammetry (FSCV) and
its adapted sister technique fast-scan controlled adsorption voltammetry (FSCAV) are
analytical techniques that employ a microscopic (7 µm diameter) carbon fiber electrode to
probe the in vivo neurochemistry in rodent models. These voltammetric techniques work
by applying an analyte-specific waveform traditionally used to study central nervous
system (CNS) dopamine. However, this technique was later adapted to probe and
understand the serotonergic system of the CNS.15, 16 Since their adaptations, FSCV and
FSCAV has been used to study real-time evoked serotonin as well as reuptake dynamics
in vivo.15, 17-22
Serotonin is a biomarker of interest because it is an essential neurotransmitter that
has long been highlighted for its importance in the regulation of mood. Therefore, it has
been postulated that the dysregulation of this transporter could result in mood disorders
like depression. Specifically, the monoamine hypothesis of depression has long been
acknowledged serotonin as a primary suspect in depression pathology.23, 24 Serotonin (and
its precursors and metabolites) have been shown to be decreased in the cerebrospinal fluid25
(CSF) and blood of depressed patients.26 However, this is not always reproducible27
suggesting it is not a good biomarker for depression. Arguably, the best support of the
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monoamine hypothesis is that many of the most efficacious ADs prescribed today target
these monoamine systems.28, 29 Fast voltammetry also offers the capability to look at and
understand pharmacodynamics from multiple vantage points including phasic release,
ambient dynamics. This work sets out to utilize/establish fast-voltammetry as a clinical
screening tool to look at the efficacy of commonly prescribed and atypical ADs as well as
to highlight the versatility and power of this technique. In this work, we compare multiple
classes of ADs to understand their effects on the serotonergic system, our biomarker of
choice. We utilize stimulated data to analyze reuptake dynamics (Ampmax and t1/2) as well
as ambient analysis to understand how these drugs change extracellular serotonin over
time. This unique combination of efforts/techniques has never been achieved, and we show
that although serotonin may not be affected in phasic stimulation dynamics, most of these
treatments show capacity to increase extracellular serotonin levels. Thus, placing serotonin
to the forefront, once more, as a main pharmacological target for treating depression.
MATERIALS AND METHODS
Chemicals and Reagents
Ketamine hydrochloride (Vet One, MWI Animal Health, Boise, ID, USA), escitalopram
oxalate (Sigma Aldrich, St. Louis, MO, USA), pargyline hydrochloride (Sigma Aldrich,
St. Louis, MO, USA), fluoxetine hydrochloride (Sigma Aldrich, St. Louis, MO, USA)
and reboxetine mesylate hydrate (Sigma Aldrich, St. Louis, MO, USA), were individually
dissolved in sterile saline (0.9% NaCl solution, Hospira, Mountainside Medical
Equipment, Marcy, NY, USA) and administered via intraperitoneal injection (i.p.) at 10
mg kg-1 and a volume of 5 mL kg-1 body weight. Urethane (Sigma Aldrich, St. Louis,
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MO, USA) was dissolved in sterile saline at 25% w/v and administered at 7 µL/g mouse
body weight for surgical anesthesia.
Electrode Fabrication
Carbon Fiber Microelectrodes (CFMs) were made individually by aspirating a single
carbon fiber (Goodfellow Corporation, PA, USA) into a 0.6 mm x 0.4 mm glass capillary
(A-M Systems, Inc., Sequim, WA). The capillary was then pulled in a vertical puller
(Narishige, Tokyo, Japan) to create a carbon-glass seal. The exposed carbon fiber was
then trimmed to 150 ± 5 𝜇m. Liquion (LQ-1105, 5% by weight NafionTM, New Castle,
DE, USA) was electrodeposited onto the surface of the carbon fiber by submerging the
fiber in Nafion and applying a constant potential of +1.0 V for 30 s. The electrode was
then dried at 70°C for 10 minutes and used after 24 hours.
Animal and Surgical Procedures
Mice (C57BL/6J) (Jackson Laboratory, Bar Harbor, ME, USA) were injected
with a 25% urethane solution based on a calculation that is dependent on their weight
(7µL/g). Following anesthetic administration, the mouse was placed into a stereotaxic
system (David Kopf Instruments, Tujunga, CA, USA) where body temperature was
maintained via heating pad (Braintree Scientific, Braintree, MA, USA). Three holes were
drilled into the skull of the mouse based off of coordinates from the mouse brain atlas.
The working electrode was placed in the CA2 region of the hippocampus (CA2: -2.91,
+3.35, -2.50) the stimulating electrode (insulated stainless-steel, diameter 0.2 mm,
untwisted, Platistics One, Roanoke, VA, USA) was placed in the medial forebrain bundle
(MFB: -1.58, +1.00, -4.80) and the pseudo-Ag|AgCl reference electrode (made by
chloritizing a silver wire in a solution of 1 M HCl for 30 secs at 5 V) was placed in the
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opposite hemisphere of the brain as the working and stimulating electrodes. Stimulation
was accomplished via linear constant current stimulus isolator (NL800A Neurolog,
Medical Systems Corp, Great Neck, NY, USA) with the following parameters: 60 Hz,
360 µA each, 2 ms in width and 2 s in length. Animal use followed NIH guidelines and
complied with the University of South Carolina Institutional Animal Care and Use
Committee under an approved protocol.
Hardware for Data Collection and Analysis
FSCV and FSCAV were performed using a Dagan Potentiostat, (Dagan
Corporation, Minneapolis, MN, USA), National Instruments multifunction device USB6341 (National Instruments, Austin, TX, USA), WCCV 4.0 software (Knowmad
Technologies LLC, Tucson, AZ, USA) and a Pine Research headstage (Pine Research
Instrumentation, Durham, NC, USA). Data filtering (zero phase, Butterworth, 2 kHz lowpass) and signal smoothing were done within the WCCV software. The “Jackson”
waveform was applied to elicit the redox properties of serotonin (+0.2V to +1.0V to 0.1V to +0.2V, 1000 V s-1). For FSCV data collection, this was applied at 10 Hz. For
FSCAV data collection, this was applied at 100 Hz. A more detailed account for FSCAV
data acquisition can be found in Chapter 2 and 3.
Statistical Analyses
Control files were averaged (4) per animal found in black for each drug. Animals that were
excluded were outliers based on a Grubbs test and animals that did not survive to the 100
min mark after drug administration. Standard error of the mean was propagated to show
error among the groups based on the n-count of the animals per drug. Significance between
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two groups were found via a 2-tailed paired t-test (p < 0.05). FSCAV estimations of basal
concentration of serotonin were analyzed via two-way analysis of variance (ANOVA) with
effects of mouse and pharmacological treatment (control, saline and drug separated by
time). Analysis of covariance (ANCOVA) was used with basal estimations of serotonin to
identify significant changes in the rates of change of concentrations. Tukey-Kramer posthoc tests were used to compare all the individual groups once significant effects on the
ambient levels of serotonin were found. Exclusion criteria were based on outliers (via
Grubbs test) and animals that did not survive the experimental paradigm.
RESULTS AND DISCUSSION
Voltammetric serotonin analysis can be used to probe the response of brain serotonin to
ADs. In Fig. 4.1 we show the histograms of the ambient level responses of extracellular
hippocampal serotonin in anesthetized mice to a variety of common AD treatments in terms
of their increase from baseline as well as the rapidity of the response (slope). We find that
most of the commonly prescribed ADs effectively target hippocampal serotonin and
administration of these agents rapidly increases extracellular serotonin after equivalent
acute doses. Though these ADs act via different modes of action, they still all show a robust
change in the ambient release from control data. Following, each data set will be analyzed
to further probe this robust increase in basal serotonin. The following is part review / part
data and will proceed chronologically, from the first synthesized ADs (TCAs) and will end
with atypical ADs (ketamine). Of particular note, we will investigate the properties of new
pharmacological agent as well as describe a rationale for the robust ambient changes upon
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ketamine administration. Both of these mechanisms center on the inflammatory system and
serotonin connection.

Figure 4.1: Ambient Pharmacological Changes to the Serotonergic System Summary
(A) Percent change from extracellular hippocampal serotonin baseline was calculated for
each drug. (B) Slope changes were compared across each drug, to show the effects on
ambient release of serotonin. (C) Table summary of figures 4.1A and 4.1B with statistical
significance denoted by * (p-value ≤ 0.05).
Tricyclic Antidepressants (TCAs)
Imipramine, the first TCA, was synthesized in 1951 and was approved for medical
use in1957.30 Imipramine strongly binds to SERT (1.3-1.4 nM Km), NET (2037 nM Km) and histamine H1R (7.6-37 nM).31 TCAs were initially prescribed as an
antihistamine, then an antipsychotic and finally for the treatment of anxiety and
depression.32 Due to TCA’s harsh side-effects (including tachycardia, hypothermia) and its
high toxicity, they were quickly phased out of clinical use.28 However, TCAs, like
imipramine, are still used as second-line treatments and for the treatment of major
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depression cases. Over the years, SSRIs have been shown to be more tolerable than TCAs;
withdrawal rates for SSRIs was 13.9% and for TCAs 18.8% (4.9% difference statistically
significant).28 There have been reported cases of TCA toxicity over the years and more
patients find themselves taking themselves off the TCA opposed to continue using it as a
treatment.33 This discounted used of the TCA is primarily due to the lack of alleviated
symptoms but also due to the adverse side effects.
Our analysis of TCAs is limited due to a combination of factors. We attempted to
use 3 TCAs (imipramine, desipramine and amitriptyline) and, at several doses, and they all
lead to death of our anesthetized mice. We have attributed this issue to two things: 1) the
harsh side effects of this class of ADs and 2) a serotonin syndrome pathway that was shown
in our basal data—this in conjuncture of the combination of the drug itself with our
anesthetic that we give our mice: urethane. This hypothesis is based on the immediate
elevation of serotonin followed by a “dip” below baseline ending in the mice’s death.
Monoamine Oxidase Inhibitors (MAOIs)
MAOIs are a class of ADs that pharmacologically target the intracellular
degradation of monoamines via inhibition of the enzyme MAO-A, MAO-B or a
combination of the two.34, 35 This class of ADs hit the market in the 1960s and later fell
out of the commonly prescribed ADs due to other, more effective lines of treatment
coming to the forefront (i.e. SSRIs and NRIs).36 One of the most common MAOI that
was, and still is, prescribed in some cases is pargyline. Pargyline acts primarily on MAOB and has been shown in the literature to robustly increase serotonin ambient levels via
microdialysis experiments.37 MAOIs were found to be effective in treating treatmentresistant depression and major depressive disorder—however they were discontinued due
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to hypertensive effects due to the adverse side effects, MAOIs are recommended as thirdor fourth-line treatments; although some doctors will recommend it earlier for treatmentresistant or atypical depressive patients.37 However, there are newer MAOIs that are
administered transdermally and do not require the same dietary restrictions that have been
seen to increase the severity of side effects.38
Voltammetric analysis of serotonin was used to further study the effects of
pargyline on the serotonergic system. In all experimental paradigms (figures 4.2-4.4, 4.6
& 4.7), we employee both FSCV and FSCAV to understand reuptake dynamics pre- and
post-drug administration and ambient changes due to the drugs effect on the CNS. In these
experiments, a carbon fiber microelectrode is placed into a mouse hippocampus to monitor
serotonin. First, serotonin is confirmed via four stimulated control files, averaged in every
dataset in black (error is standard error of the mean in the lighter shade around the line).
We then employ FSCAV analysis and monitor the ambient serotonin for 30 min as a
control, then administer saline to the animal and see no statistically significant changes.
We then administer our pharmacological agent and monitor ambient changes over an hour
of data collection. Then, we switched back to stimulated analysis to look at the changes in
phasic/stimulated release of serotonin due to each drug. In each experiment that follows,
we explore the effects that are imparted on serotonin from administration of these
commonly prescribed and emerging ADs. Serotonin remains an important molecule in the
context of depression, therefore, our goal was to expand the understanding of serotonin’s
effects on the CNS by monitoring how hippocampal serotonin responded to a subanesthetic dose of pargyline (10 mg kg-1). We find that the phasic levels of serotonin do

67

not statistically change, but contrary to the literature, we see an immediate dip in ambient
serotonin upon pargyline administration.
Figure 4.2.A highlights a key finding that acute pargyline has effect on serotonins
stimulated or phasic release we see this twofold: 1) t1/2 and 2) Ampmax pre- and postpargyline. The t1/2 went from 2.1 ± 0.5 s to 2.9 ± 0.4 s (NS), there is a trend towards an
increase here. The Ampmax went from 29.5 ± 6.0 nM to 42.1± 13.6 nM (NS), showing a
similar trend towards an increase. Figure 4.2.B indicates that there is a no change in
ambient serotonin levels after drug administration from control to 60 min after pargyline
administration (post-hoc test, 40.72 ± 1.90 vs. 37.08 ± 19.09 nM, p = 1.000). Additionally,
the slopes of the time series for the control, saline and post pargyline acquisition do not
differ significantly (ANCOVA test, F = 0.3604, p = 0.7859). This is no robust ambient
change and differs from the literature associated with this drug. One thought here is that
the microdialysis literature saw these increase in ambient serotonin at a much slower
sampling rate; however, data acquisition of our technique is begins within 30 secs of drug
administration. We do see at the end of the hour-long ambient experiment, that levels
slowly increase. Though this is not significant, we plan to explore this instantaneous drop
in serotonin levels to evaluate and tease out this stark difference from the literature values.

68

Figure 4.2: Pargyline-induced changes in serotonin. (A) Extracellular hippocampal
serotonin at baseline (black), post saline injection (grey), and post pargyline (i.p. 10 mg kg1
, red) (n=5, male + female mice). (B) Evoked hippocampal serotonin at baseline (black)
and 70+ min post pargyline (red). Stimulation is marked by a yellow box at 5-7 s. Statistical
significance is marked by an * (p < 0.05).
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs have been used as the frontline treatment for depression since the rollout of
fluoxetine in 1987.39 This class of drugs are small organic molecules, structurally
resembling serotonin, that inhibit the serotonin transporter (SERT), a protein tasked with
clearing the monoamine after synaptic release.40 However, the therapeutic mechanism of
action of SSRIs remains unknown since the effects of these drugs on in vivo serotonin
chemistry in the brain is hard to assess. However, generally, it is accepted that the
pharmacological pathway of SSRIs works by selectively targeting and blocking the
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SERTS, thereby increasing the concentration of serotonin in the synaptic cleft and the spill
over into the extracellular space.41
SSRIs are the most commonly prescribed AD and this is due to the efficacious rate
of these drugs as well as their less harmful side effects than other classes of ADs.42 As a
patient continues their treatment, the overall levels of serotonin have been hypothesized to
reach a homeostatic maximum and the depressed patient begins to feel symptom
alleviation. This efficacy is thought to be due to, but not limited to, desensitization of the
serotonin autoreceptors and SERTs over the prolonged SSRI administration.43, 44
For this portion of this work, we focused on the first SSRI come to market and the
most clinically efficacious: fluoxetine and escitalopram, respectively. Again, we focus on
the reuptake dynamics via FSCV analysis and ambient changes via FSCAV analysis. We
explored the role that serotonin plays in this emerging depression from effects of these
commonly prescribed ADs. We wanted to investigate effects to hippocampal serotonin in
response to a sub-anesthetic dose of fluoxetine (20 mg kg-1) and escitalopram (10 mg kg1

). We find that serotonin phasic release is changed upon both drug administration as well

as an increase in basal levels.
Figure 4.3.A highlights a key finding that acute fluoxetine has effect on the
stimulated release of serotonin, and we see this twofold: 1) t1/2 and 2) Ampmax pre- and
post-fluoxetine. The t1/2 went from 2.3 ± 0.3 s to 4.9 ± 0.5 s (p < 0.05), this shows a
significant increase and therefore is evidence that fluoxetine has an effect on blocking
SERTs, and may illustrate the reason fluoxetine is an efficacious treatment for depression.
The Ampmax significantly increased from 31.5 ± 7.7 nM to 53.4 ± 11.5 nM, this shows a
statistical change and therefore shows evidence of that fluoxetine does have an effect on
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blocking transporters and increasing the amout of serotonin present, this is again probably
due to the blocking and binding of the drug to SERTs, further illustrating the reason
fluoxetine is an efficacious drug for depression treatment. However, Figure 4.3.B indicates
that there is a robust change in ambient release of serotonin from the control state to 60
min after drug administration (post-hoc test, 48.89 ± 1.86 vs. 73.31 ± 11.82 nM, p =
0.0150). This represents a 49% increase respect to the initial basal levels. Additionally,
using an ANCOVA test and post-hoc multiple comparisons, the slopes of the time series
for control and after fluoxetine administration were found to be significantly different
(post-hoc test, slope = -0.02 vs. 0.22 nM/min, p < 0.0001). robust ambient change is on
par with the literature trends for this commonly prescribed AD.

Figure 4.3: Fluoxetine-induced changes in serotonin. (A) Extracellular hippocampal
serotonin at baseline (black), post saline injection (grey), and post fluoxetine (i.p. 20 mg
kg-1, green) (n=5, male + female mice). (B) Evoked hippocampal serotonin at baseline
(black) and 70+ min post fluoxetine (green). Stimulation is marked by a yellow box from
5-7 s. Statistical significance is marked by an * (p < 0.05).
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Figure 4.4.A highlights a key finding that acute administration of escitalopram
affects the stimulated release of serotonin in two ways: 1) t1/2 and 2) Ampmax pre- and postescitalopram. The t1/2 significantly increased from 1.7 ± 0.1 s to 9.1 ± 1.6 s (p < 0.05) over
30 minutes. The Ampmax significantly increased from 17.4 ± 4.4 nM to 35.5 ± 10.3 nM.
The combined increase in t1/2 and Ampmax shows that escitalopram effectively blocks
SERTs to increase the extracellular levels of serotonin in the brain. However, Figure 4.4.B
indicates that there is a robust change in ambient release of serotonin from control
acquisition to 60 min after drug administration (post-hoc test, 48.89 ± 1.86 vs. 73.31 ±
11.82 nM 10.86 nM, p = 0.0108). This represents an 87% increase respect to the initial
basal estimations of serotonin. Additionally, using an ANCOVA test and post-hoc multiple
comparisons, the slopes of the time series for control and after escitalopram administration
were found to be significantly different (post-hoc test, slope = 0.01 vs. 0.40 nM/min, p <
0.0027). This robust ambient change is on par with the literature trends for this commonly
prescribed AD.
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Figure 4.4: Escitalopram-induced changes in serotonin. (A) Extracellular hippocampal
serotonin at baseline (black), post-saline injection (grey), and post-escitalopram (i.p. 10 mg
kg-1, blue) (n=10, male + female mice). (B) Evoked hippocampal serotonin at baseline
(black) and 70+ min post escitalopram (blue). Stimulation is marked by a yellow box from
5-7 s. Statistical significance is marked by an * (p < 0.05).
These SSRIs show similar mechanisms on both the reuptake and ambient levels via
our analysis of the serotonergic system. This illustrates further that most SSRIs do act
similarly on a pathway. It should be noted that these two SSRIs are currently the most
common ADs prescribed to depressed patients today.45 We have shown here that these
drugs are both robustly increase extracellular serotonin levels in mice models and that
escitalopram is more effective at increasing basal levels, which is in line with its better
clinical efficacy.
Though the frontline pharmacological therapy for depression are SSRIs they do not
bring clinical relief to the majority of patients who take them. Up to 60% of the depressed
population do not respond to SSRI treatments, forcing patients to either try the few atypical
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ADs available or go without medication. There is no explanation for the variable efficacy
of SSRIs and has led to a lull in drug discovery for alternative ADs because there is no new
data to help navigate these efforts. There is now a growing body of evidence that
inflammation plays an important role in this diminished clinical response46-48.
Inflammation is a blanket term to describe a state of immune-activation49 where immune
cells prompt a biochemical cascade (e.g. cytokines) to identify and remove the source of
inflammation (such as infection). An important, but largely damaging aspect of
inflammation is oxidative stress50 which is hallmarked by generation of reactive oxygen
species (ROS)50. Oxidative stress causes significant acute and chronic macromolecular and
cellular damage50. While this process is the subject of investigation in many chronic
illnesses, oxidative stress caused by inflammation co-morbid with depression is only
recently being appreciated51.
The damaging effects of oxidative stress can be easily curtailed via antioxidant
therapies that scavenge ROS. Therefore, there may be therapeutic potential in combining
SSRI and antioxidant therapy. In conjunction with another research group, our lab has
recently developed a novel antidepressant-antioxidant agent in a selenium-modified
fluoxetine molecule52. Such drug-like chimeric compounds are designed with the aim of
combining the SSRI effect of fluoxetine with the enhanced antioxidant, ROS-scavenging
activity granted by selenium. We aimed to understand and evaluate the selenofluoxetine
fluorinated-derivative’s ability to inhibit in vivo serotonin reuptake in mice. We therefore
present an exciting new strategy to target both serotonin and oxidative stress as the next
generation of antidepressant. We do this by comparing the analogous model fluoxetine to
this newly synthesized drug.
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A control serotonin signal was isolated in 5 mice in the CA2 region of the
hippocampus in a mixed sex cohort (Fig. 4.5.A: blue). After 4 control files were collected,
the F-Se-derivative was administered via i.p. injection at 50 mg kg-1. After 30 minutes, the
signal was taken and averaged between the mice (Fig. 4.5.A: orange). Serotonin release
amplitude increased from 22.73 ± 4.07 nM to 25.84 ± 3.41 nM (N.S.) and the t1/2 of
reuptake was found to significantly increase from 1.93 ± 0.30 s to 3.38 ± 0.41 s (p < 0.05).
A further set of experiments in a separate mouse cohort was performed in the same way,
however this time classic fluoxetine was administered at 20 mg kg-1 (Fig 4.5.B: orange).
We found a significant amplitude increase from 35.75 ± 10.16 nM to 56.05 ± 13.40 nM
and a significant t1/2 increase from 1.90 ± 0.46 s to 4.01 ± 0.70 s (p < 0.05).
Fluoxetine has a more pronounced effect on the serotonin signal than the F-Sederivative, despite the lower dose. We believe this is a consequence of two effects. Firstly,
the electronegativity conferred by the oxygen group in fluoxetine plays an important role
in the way the SSRI binds to the SERTs41 Secondly, the Se-C bond could be more easily
hydrolyzed than the O-C bond because the valence electrons in the Se-C bond are more
shielded from the nucleus because of its size of the Se atom.17 Nevertheless, this new agent
does have ability to inhibit serotonin reuptake, and therefore positions this drug up as a
possible therapeutic for depression. Further evidence to support the effects on serotonin
reuptake of this newly developed compound is our Michaelis-Menten analysis. For both
fluoxetine and the new analog, we see that the Vmax (maximum rate of reuptake) decreases
upon the administration of the agent. For fluoxetine, the Vmax trends from 17.69 to 15.21
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nM/s and for the F-Se-derivative the Vmax trends from 15.60 to 13.46 nM/s. Thus, our new
compounds show promising chemical efficacy for slowing serotonin reuptake.

C

Figure 4.5. In Vivo Stimulated Serotonin Release in the CA2 region of the
hippocampus. (A) Representative color plots for this experimental paradigm, before and
30 mins into drug analysis, are found above the representative IT curves. The averaged
control evoked serotonin in mixed sex cohort can be found in blue (n = 5) with SEM
calculated and outlined in the lighter shade of blue. The averaged drug files (F-SeFluoxetine, 50 mg kg-1) at 30 mins for serotonin in mixed sex cohort is plotted in orange
(n = 5) with SEM calculated and outlined in the lighter shade of orange. Stimulation is
indicated via the gray bar. (B) Representative color plots for this experimental paradigm,
before and 30 mins into drug analysis, are found above the representative IT curves. The
averaged control evoked serotonin in mixed sex cohort can be found in blue (n = 5) with
SEM calculated and outlined in the lighter shade of blue. The averaged drug files
(Fluoxetine, 20 mg kg-1) at 30 mins for serotonin in mixed sex cohort is plotted in orange
(n = 5) with SEM calculated and outlined in the lighter shade of orange. Stimulation is
indicated via the gray bar. Statistical analysis can be found for each data set in table 4.1.
(C) Shows the molecular structure of both drugs used during this experimental procedure.
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Table 4.2 Features of in vivo Experimental Curves
Maximum Release
(nM)

𝑡1/2 of Clearance

Vmax

(s)

(nM/s)

Control Pre-Fluoxetine

35.75 ± 10.16

1.90 ± 0.46

17.69

30 min Post-Fluoxetine

56.05 ± 13.40*

4.01 ± 0.70*

15.21

Control Pre-1F Se-

22.73 ± 4.07

1.93 ± 0.30

15.60

25.84 ± 3.41

3.38 ± 0.41*

13.46

Fluoxetine
30 min Post-1F SeFluoxetine
Mean ± SEM (n = 5 animals) of the maximum evoked serotonin amplitude (𝐴𝑚𝑝𝑚𝑎𝑥) and
clearance rate (𝑡1/2). Each parameter was tested for significant difference between control
and drug treatment (paired samples t-test). Significance (*) was defined as p < 0.05.
Michaelis-Menten reuptake kinetics model for serotonin was fitted to the signal. 𝐾𝑚 was
set to 5 nM, while 𝑉𝑚𝑎𝑥 was optimized to fit the average experimental trace.
Norepinephrine Reuptake Inhibitors (NRIs)
NRIs are subclass of ADs that primarily inhibit norepinephrine transporter
(NETs), effectively increasing extracellular concentrations norepinephrine and
epinephrine. The first widely prescribed NRI was reboxetine, introduced to market in
1997: reboxetine.53 Reboxetine has high affinity for NETs (Km = 13.4 nM) comparted to
its affinity for SERTs (Km = 273.5), which is about 20-fold selectivity.54 Despite this
stark affinity difference, reboxetine has been shown to inhibit the serotonin reuptake.55
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For this portion of the work, we focused on studying the direct effects of reboxetine on
the serotoninergic system by, again, focusing on the reuptake dynamics via FSCV
analysis and ambient changes via FSCAV analysis. We find that phasic serotonin release
is altered upon administration of a sub-anesthetic dose of reboxetine (20 mg kg-1),
expanding the understanding of serotonin dynamics in response to a non-serotonin
targeting AD.
Figure 4.6.A highlights the effect of an acute dose of reboxetine on the stimulated
release of serotonin via analysis of: 1) t1/2 and 2) Ampmax pre- and post-reboxetine. The t1/2
significantly increased from 2.9 ± 0.2 s to 5.9 ± 1.5 s (p < 0.05). The Ampmax significantly
increased from 44.8 ± 7.1nM to 53.4 ± 1.5 nM. This begins to illustrate the power of
downstream effects on increasing serotonin in neuronal space. Additionally, Figure 4.6.B
indicates a robust change in ambient release of serotonin from control acquisition to 60
min after drug administration (post-hoc test, 34.43 ± 1.08 vs. 62.43 ± 19.79 nM, p =
0.0302). This represents a 79% increase respect to the initial basal estimations of serotonin.
Using an ANCOVA test and post-hoc multiple comparisons, the slopes of the time series
for control and after escitalopram administration were found to be significantly different
(post-hoc test, slope = 0.04 vs. 0.15 nM/min, p = 0.0014). This is on par with literature
trends.
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Figure 4.6: Reboxetine-induced changes in serotonin. (A) Extracellular hippocampal
serotonin at baseline (black), post-saline injection (grey), and post-reboxetine (i.p. 20 mg
kg-1, purple) (n=5, male + female mice). (B) Evoked hippocampal serotonin at baseline and
70+ min post reboxitine. Stimulation is marked by yellow box from 5-7 s. Statistical
significance is marked by an * (p < 0.05).
Modern ADs: Ketamine
Ketamine, an anesthetic, has recently been proposed to be used as an AD for
patients with major depressive disorder. This drug is not used as a frontline treatment for
depression, but it has been shown to be efficacious for patients that do not respond to
traditional antidepressants.56 Though ketamine has shown promise as an AD, over time its
effects become less and require higher doses.57-60 The exact mechanism in which ketamine
acts as an antidepressant is not well-defined, but ketamine is a known N-methyl-Daspartate (NMDA) receptor antagonist.61 Therefore, ketamine doesn’t function the same as
“classical” ADs, i.e. it does not act directly on monoaminergic systems. Ketamine is
known to act primarily on glutamatergic and GABAergic pathways.62 The metabolic
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products of this drug from (R/S)-ketamine to (2R,6R;2S,6S)-hydroxynorketamine has been
shown to be a key feature of ketamine's effects as an AD; with the S enantiomer having
stronger affinity for the long-lasting AD effects.63, 64
Most work to understand ketamine’s AD effects has centered on GABA, glutamate
and serotonin. So again, we investigate what an acute dose of ketamine (10 mg kg -1) does
to hippocampal serotonin both in its stimulated and ambient release. Figure 4.7.A
highlights a key finding that after an acute dose of ketamine the t1/2 increased from 1.8 ±
0.2 s (control, black) to 2.5 ± 0.3 s (post-drug, yellow) (NS). Since there is no significant
change in uptake time pre- and post-ketamine, there is no alteration in the reuptake of
serotonin back into the presynaptic neuron. Similarly, there was no significant change in
the Ampmax from the control at 32.3 ± 10.9 nM to our post drug signal at 32.2 ± 10.2 nM,
showing no change in the release of serotonin via electrical stimulation. However, Figure
4.7.B indicates there is a significant change in ambient release of serotonin from control
acquisition to 60 mins after ketamine administration (post-hoc test 27.91 ± 0.95 vs 40.82
± 6.97 nM, p = 0.0001). This represents a 46% increase with respect to the initial basal
estimation of serotonin. Using an ANCOVA test and post-hoc multiple comparisons, the
slopes of the time series for control and after ketamine administration were found to be
significantly different (post-hoc test, slope = -0.05 vs. 0.26 nM/min, p < 0.0001). This
robust increase in ambient serotonin is consistent with microdialysis work for this atypical
antidepressant. Further work needs to be done to investigate the discrepancy between the
stimulated and basal levels of serotonin in response to ketamine.
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Figure 4.7: Ketamine-induced changes in serotonin. (A) Extracellular hippocampal
serotonin at baseline (black), post saline injection (grey), and post ketamine (i.p. 10 mg kg1
, gold) (n=5, male + female mice). (B) Evoked hippocampal serotonin at baseline (black)
and 70+ min post ketamine.
As previously stated, ketamine does not act directly on the serotonergic system and
is thought to be mediated via the glutamatergic or GABAergic systems. In the following
section, we explore an alternative pathway of depression via histaminergic mediation.
Depression is highly comorbid with inflammation, and we have recently shown that
histamine directly mediates serotonin signaling in the brain.65,

66

Therefore, we will

examine the downstream effects of ketamine on the histaminergic system in order to
understand this discrepancy between stimulated and ambient hippocampal serotonin levels.
In this data set, we found that systemic administration of ketamine causes rapid and
sustained inhibition of hypothalamic histamine and attenuates histaminergic inhibition of
serotonin. As such ketamine increases the ambient levels of serotonin in a manner
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synonymous to standard SSRIs. Our results thereby help to uncover ketamine’s rapid AD
effects on the ambient system.
Histamine is a neurotransmitter that is thought to be related to the antithesis of
serotonin. Therefore, if histamine levels increase, serotonin levels concomitantly
decrease. So, it is of interest to study histaminergic changes due to the administration of
ketamine. In this experimental paradigm, we again administer the same acute dose of
ketamine via the i.p. cavity and monitor the changes in histamine dynamics over two
hours. We saw that ketamine caused a robust and persistent decrease in evoked histamine
seen in Figure 4.8.A-C. We saw a significant change in amplitude in control files vs drug
files from 8.92 ± 1.80 µM to 6.09 ± 1.61 µM (p = 0.005). However, there was no
significant effect on clearance rate from a control of 4.1 ± 1.1 s to a drug response of 3.3
± 0.8 s (p = 0.23). Overall, we saw an inhibition of evoked serotonin peak amplitude
from controls: 44.70 ± 7.91 nM to post-drug files: 20.12 ± 4.88 µM (p = 0.013). There
was a rapid and prolonged suppression of histamine all throughout data collection (100
min), and subsequent relief of the serotonin inhibition. This is indicative that ketamine
indirectly inhibits the release of histamine and therefore rapidly imparts change on
ambient serotonin levels.
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Figure 4.8. Histamine Response to Ketamine. Panel A is a representative color plot for
simultaneous histamine and serotonin monitoring with the associated colorplot
interlayed. Panel B depicts the IT curves for histamine (top) and serotonin (bottom) preand post-ketamine. Panel C shows the change in the colorplot 10 mins after drug
administration. Panel D depicts the evoked histamine amplitude over time where Panel E
shows the inhibition of serotonin amplitude over time.
Overall, we have shown how ketamine, at a low acute dose, has the ability to
indirectly and rapidly increase serotonin. These advantageous effects of serotonin increase
are thought to stem from glutamate activated Alpha-amino-3-hydroxy-5-methyl-4isoxazole propionic acid (AMPA) receptors, increased abrineurin, activation of
mammalian target of rapamycin (mTOR), inhibition of glycogen synthase kinase-3;
however, it is most likely a likely a combination of all the previously mentioned.67-69 These
have all been studied and ultimately show effect to increase serotonin levels.70 This in
combination with the evidence that ketamine acts in an anti-inflammatory manner and
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decreases pro-inflammatory cytokines71 and the data presented sets ketamine as true AD
agent toward serotonin.
CONCLUSIONS
In this chapter, we have given a brief history, analyzed stimulated releases and
ambient changes of four classes of antidepressants effects on the serotonergic system. We
have shown that these drugs all act differently on stimulated release of serotonin. But the
stark takeaway is though these drugs act via different pathways and systems,
escitalopram, fluoxetine, reboxetine and ketamine have all been shown to robustly
increase concentration of basal serotonin. We have also shown the promise for a new
emerging AD as well as offer a mechanism for the rapidly increase of serotonin upon
ketamine administration. In chapter 5, we will revisit the drug’s basal data sets and
analyze it through a new lens. Thus, further cementing FSCAV as a versatile tool for
neurochemical analysis.
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Chapter 5: FSCAV Parameter Optimization for Improved
Definition and Temporal Resolution of Ambient Serotonin
Oscillations1

1

Witt, C.E., Islam, F., Honan, L. E., Mena, S., Ou, Y., Cook, J. & Hashemi, P. FSCAV
Parameter Optimization for Improved Definition and Temporal Resolution of Ambient
Serotonin Oscillations. In preparation. Analytical Methods.
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ABSTRACT
The behavior of serotonin in the brain is extensively studied because of its implication in
many mood disorders, including depression. The evoked release and reuptake of this
neuromodulator is well-understood, but the ambient levels of serotonin also reveal
functionality and are of benefit to study and understand. Experiments using fast-scan cyclic
voltammetry have shown that serotonin is more tightly regulated compared to other
neurochemicals such as dopamine. The ambient concentration levels of serotonin in the
extracellular space offer additional insight on their regulatory behavior and can be studied
using fast-scan cyclic adsorption voltammetry (FSCAV). Preliminary in vivo data revealed
that the ambient concentration of serotonin demonstrates distinct oscillatory patterns. A
series of in vitro experiments where the time parameters of FSCAV were systematically
adjusted were performed to improve the temporal resolution and ultimately isolate these in
vivo oscillations from technical noise. With the aid of mathematical modeling, mechanism
of oscillatory behavior is explored. Ultimately, optimized parameters of FSCAV aim to
further surpass the Nyquist Limit and improve the technical noise filtering paradigm used
to help further define the in vivo ambient regulatory patterns of serotonin.
INTRODUCTION
Mood disorders are a class of psychiatric illnesses that disrupt emotion,
motivation and wellbeing over prolonged periods.1 The most common mood disorders
include the spectrum of major depressive and bipolar disorders.1 2 The symptoms of
depression are comprised of a range of emotional and physiological changes that
negatively impact an individual’s ability to function and complete daily activities.1 2
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21.4% of U.S. adults have experienced depression over their lifetime and the prevalence
of depression is growing.2
To date, diagnostics of depression is via a questionnaire that bases the
symptomology off the defined criterion found in the DSM-5 and ultimately diagnosis is
based off the discretion of a physisician.1 There is no current chemical diagnostic test,
unlike for many diseases of the periphery, which makes it difficult to chemically identify
depression in patients.1,

2

Diagnosed depressed patients are prescribed antidepressant

therapies and often cycle through several antidepressants at various doses before
depression symptoms are alleviated. This process often takes several months and thus the
risk for harsh side effects are prolonged.1
To develop a diagnostic test and an improved treatment process, chemical
biomarkers of depression in the brain must be investigated. However, these chemical
biomarkers are difficult to identify due to the isolated and protective nature of the brain
and neurotransmission.2 Neurotransmitters act as chemical messengers when they are
released by neurons at the synapse after an action potential.3 The monoamine hypothesis
of depression theorizes that an imbalance of specific neurotransmitters contributes to the
pathophysiology of depression. A deficiency or excess in levels of serotonin, dopamine
(DA), and/or norepinephrine (NE) can cause dysregulation in the brain and lead to the onset
of depression.3
Serotonin is a neuromodulator, a specific type of neurotransmitter, that is released
at a high volume.2 The high-volume transmission causes spill over beyond the synaptic
cleft into the extracellular space. This allows for neuromodulators to exert control over and
modify several cells at one time.2 Serotonin and DA are electroactive neuromodulators
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which allows for the concentrations of serotonin and DA at the synapse and in the
extracellular space to be detected using electroanalytical techniques.2,

4, 5

Specifically,

serotonin has been isolated as a possible biomarker of depression due to its efficacious
nature as a pharmaceutical target.4, 5
The electroanalytical techniques actively used to study serotonin are Fast-Scan
Cyclic Voltammetry (FSCV) and Fast-Scan Controlled Adsorption Voltammetry
(FSCAV).4, 5 Both techniques utilize the redox properties of serotonin to monitor the realtime dynamics in vivo and in vitro. A carbon-fiber microelectrode (CFM) is the niche tool
in which these techniques are applied to elucidate the precarious nature of this
neurochemical. FSCV is used to measure the evoked response of neurotransmitters, while
FSCAV is used to measure the ambient state of neurotransmitters typically present in the
extracellular space. 4, 5
As shown in Chapter 4, we can employ FSCAV to monitor ambient serotonin
levels after antidepressant administration. Due to the nature of the data presented, we
hypothesized that these data sets may also contain oscillatory patterns that have been noted
in the literature6, 7. Specifically, if we are to take individual electrodes, we notice individual
patterns in these “oscillations” (Figure 5.1A.).

88

Figure 5.1: In Vivo FSCAV Response and Filtering (A) 5 individual serotonin responses
and oscillations over time in male control mice. (B) Two separate experiments comparing
the response of the same CFM in vitro in a 75 nM solution of serotonin (blue) and in vivo
(purple). The plots are filtered using a low-pass filter in MATLAB via a fast-Fourier
Transform.
In each of these cases, we conducted an FSCAV experiment to observe subtle
oscillations in the ambient serotonin levels in the extracellular space. An electrode was
placed in the CA2 region of the hippocampus in control mice (n = 5) and the data was
collected during the mouse’s light cycle; the data is displayed in Figure 5.1.A. This shows
that there are oscillations in serotonin concentration and that these oscillations are unique
for each individual mouse. We believe these oscillations are biologically relevant and
hypothesize that they represent a feedback mechanism that serves to control extracellular
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mechanisms. However, we need to take these experiments a step further to further confirm
that we are looking at oscillations that are not an artifact of the technique. To establish the
nature of the oscillations, the following experimental procedure was employed: an
electrode was placed in beaker of 75 nM serotonin solution and files taken over an hour
time period. This data was then analyzed and plotted in blue in Figure 5.1.B (pC). After
the in vitro experiment, the same electrodes were placed into the hippocampus of an
anesthetized mouse and FSCAV data of serotonin was taken in vivo on that animal. The in
vivo and in vitro data obtained from the oscillation curves underwent a fast-Fourier
transform using a low pass filter from MATLAB (see figure 5.1). In vitro the signal is
relatively unchanging (blue), whereas in vivo (purple) we see oscillations on a ~20-minute
time scale. We believe that these oscillations are due to a feedback loop defined by reuptake
mechanisms and properties for serotonin. In this work, we apply this analysis to in vivo
experiments before after antidepressant administration, we find interesting shifts that speak
to feedback loops in vivo. However, we conclude that to find significance in our work, it
would be in best interest to increase the temporal resolution of FSCAV itself.
Thus, the FSCAV technical parameters were optimized to measure ambient
serotonin. To generate a more robust filtering paradigm, the technical noise of FSCAV
must become more distinct. The technical noise can be characterized by its frequency and
amplitude. By systematically adjusting the time parameters of FSCAV we can manipulate
the frequency and amplitude of the technical noise. High frequency noise is filtered out by
the low pass filter since the in vivo signal maintains a low frequency. Technical noise that
bypasses the low-pass filter should maintain a low amplitude so that the in vivo signal is
not obscured. This work aims to optimize the FSCAV temporal parameters by
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systematically adjusting each time parameter in biologically relevant concentrations of
serotonin in vitro to maximize the frequency and minimize the amplitude of the technical
noise. The optimized FSCAV temporal parameters will allow for faster data collection in
order to surpass the Nyquist Limit and define the in vivo ambient regulatory patterns of
serotonin.
METHODOLOGY

Solutions
Dopamine hydrochloride and serotonin hydrochloride were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Liquion (LQ-1105, 5% by weight Nafion) was purchased from Ion
Power Solutions (New Castle, DE, USA). Tris buffer solution was composed of 15 mM
Tris, 140 mM NaCl, 3.25 mM KCl, 1.25 mM NaH2PO4, 2.0 mM Na2SO4, 1.2 mM CaCl2,
and 1.2 mM MgCl2, then adjusted to pH 7.4 (all purchased from Sigma-Aldrich (St. Louis,
MO, USA)). Serotonin solutions were made using serotonin hydrochloride powderand
1XTris Buffer.
CFM Fabrication
CFMs were assembled in-house by aspirating a single 7-10 µm diameter carbon fiber (T650, Goodfellow, Coraopolis, PA, USA) into cylindrical glass capillaries (internal
diameter: 0.4 mm, external diameter: 0.6 mm, A-M Systems, Carlsborg, WA, USA). The
carbon-filled capillaries were positioned vertically in a micropipette puller (Narishige
Group, Setagaya-Ku, Tokyo, Japan) to form a carbon−glass seal under gravity. The
exposed length of the carbon fibers was then cut approximately to 150 (± 5) µm for
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serotonin under an optical microscope. An electrical connection was forged to a connection
pin using silver paint and a connecting wire.
Nafion Electrodepoistion: NafionTM was electrodeposited onto the exposed carbon surface
using a constant potential of +1.0 V vs Ag/AgCl applied for 30 s. The CFMs were dried at
70 °C for 10 minutes and stored for 24 hours prior to use.
FSCAV
FSCAV data collection and analyses were performed using WCCV 3.06 software
(Knowmad Technologies, LLC, Tucson, AZ, USA), a Dagan potentiostat (Dagan
Corporation, Minneapolis, MN, USA), and a Pine Research headstage (Pine Research
Instrumentation, Durham, NC, USA). The serotonin waveform was applied scanning from
0.2 to 1.0 to -0.1 to 0.2 V at a scan rate of 1000 V/s and frequency of 100 Hz.8, 9 The holding
potential for serotonin was 0.2 V.8,

10

The signals collected from solutions of 75 nM

serotonin were processed by the same software to perform signal deconvolution, filtering,
and smoothing.
Parameter Adjustments
The original FSCAV time was systematically adjusted based on the background time,
controlled adsorption time, redox time and wait time. A sample size of 5 microelectrodes
for each adjustment was collected for serotonin, respectively. Background time was
adjusted from the original 2 s to 1 s. Controlled adsorption time was adjusted from the
original 10 s to 5 s or 1 s. Redox time was adjusted from the original 18 s to 12 s or 6 s.
Wait time was adjusted from the original 30 s to 15 s and 0 s. An example total file time
for the adjusted 15 s Redox time parameter is 45 s (2 s + 10 s + 15 s + 30 s). Each
microelectrode was used in vitro for 30 minutes.

92

Statistical Analysis: Among the electrode cohorts (n=5) for each time parameter, a twotailed paired t-test was employed to reveal statistical significance of the data. P-values are
denoted as follows: * = p<0.05, ** = p<0.025, *** = p<0.001
Data Processing
All data processing and analysis was performed using a custom-designed Python 3.6 code.
For FSCAV signals, intervals of integration of the faradaic peak were automatically found
using a local minima detection algorithm. Each interval of integration was visually
inspected and corrected when the program fails to detect the faradaic peak of interest. The
numerical integral between the faradaic peak and a linear baseline is calculated using the
Simpson’s rule.
Charge vs. time traces were filtered using a 3rd order bandpass Butterworth filter with a
designed passband between 0.0008 Hz and 0.005 Hz. The low cutoff frequency was chosen
to remove from consideration the low frequency drug effects on serotonin absolute
concentration. The high cutoff frequency removes the noise component of the signal.
Autocorrelation and sliding window correlation (SWC) using Pearson’s coefficient were
used to study the relationships between observations in the time series as a function of
delay. The autocorrelation function, expressed in Equation 1, was used to calculate the
correlation between pairs of samples distanced by a lag (p), where X denotes the mean
value across the time series of length N. [CITE Time Series Analysis: Forecast and Control]
𝑟/ =

89:
3;< (23 42)(2367 42)
8 (2 42)=
3;< 3

(1)

Similarly, SWC was used to study the association of fixed-length windows. Equation 2
shows the general formulation of the correlation function between a window of length l
starting at time t and another window of the same size distanced by a lag p.11
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Autocorrelation and SWC were calculated for all possible delays to study the presence of
oscillatory patterns in the time series. Correlation scores are tested for a significant
difference from 0 and the highest autocorrelation obtained from random white noise and in
vitro time series.
White noise was generated by drawing pseudo-randomized samples from a Gaussian
distribution of mean 0 and standard deviation matching the mean standard deviation of all
in vivo experiments presented in this study. The power spectral density (PSD) of time series
was calculated from the fast Fourier transform spectrum using the Welch method.12
Analysis of oscillatory patterns pre- and post-drug administration were performed by
comparison of the PSD peak that corresponds to the largest oscillation pattern established
with the correlation measurements.
Statistical Analyses
Statistical significance is defined as p < 0.005. All statistical tests are performed using
Python 3.6 SciPy library13 and MATLAB 2020b. Distribution of samples are shown as
mean 土 SEM. Correlation coefficients are tested to be significantly different from zero
using Student’s t-test and assuming time series to be non-stationary. Statistical significance
of changes in the power spectrum peak was tested using Student’s paired t-test.
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RESULTS AND DISCUSSION
Oscillatory Changes in Response to Pharmacological Manipulations
In Chapter 4, we investigated the effects of antidepressants on tonic concentrations
of serotonin. Above, we analyzed the oscillations in the ambient levels of serotonin to
understand what might be responsible for changes in this tightly regulated system by using
autocorrelation and sliding window correlation to certify that the oscillations are indeed
present in vivo, but not in vitro, after filtering. Rather, the filtered in vitro trace is nearly
identical to that observed for random white noise. Thus, this confirms that the pseudooscillatory pattern prior to filtering in vitro data can be directly equated to random white
noise. However, the oscillatory pattern that remains in vivo following the filtering is the
result of a biological phenomenon. This filtering method is detailed above in the methods
section under “data processing”. A representative example of this process is found in
Figure 5.2 below.
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Figure 5.2: Filtering Paradigm Expanded. Blue is an example in vitro experiment; an
electrode is placed in 75 nM of serotonin and the noise is plotted on the left. The data is
then placed through a Butterworth bandpass filter and the outcome is found on the right.
The same is done for random white noise (green) and in vivo data (red). After the filter is
applied, the in vitro data has similar features to the random white noise. Whereas, the in
vivo data shows distinct oscillations.
After the mathematical confirmation, we performed a power spectral analysis of
the charge vs. time traces to compare the spectrum of traces pre- and post-administration
of drug to see spectral changes in the oscillations. The frequency with a higher power in
the spectrum was taken as the representative oscillatory frequency of the acquisition. Prior
to drug administration, the serotonin oscillations are measured to have a period of 0.069 ±
0.005 min. Acquisitions following escitalopram and fluoxetine administration present a
period of 0.079 ± 0.005 min, 0.085 ± 0.005 min, respectively (F = 1.16, P = 0.3399).
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Following ketamine and pargyline administration the period changes to 0.071 ± 0.006 min
and 0.070 ± 0.005 min respectively (F = 1.16, P = 0.3399). Finally, following reboxetine
administration, the period changes to 0.066 ± 0.005 min (F = 1.16, P = 0.3399). In sum,
ketamine and pargyline have a negligible effect on the frequency of serotonin oscillations,
fluoxetine and escitalopram increased the frequency, and lastly, reboxetine slowed the
frequency of these oscillatory patterns. Though this data set in figure 5.7 is not statistically
significant, it begins to illustrate our hypothesis for why these frequency shifts happen.

Figure 3: Oscillation Shifts to AD Administration. Shows the average ± SEM power
spectra density pre- and post-acquisition for all the drug treatments stated above (n = 5
mice). A and B shows two SSRIs’ effects to speed up frequency of oscillatory patterns. C
and D shows two drugs that do not directly act on transporters and show no change in
oscillatory patterns. E shows an NRIs’ effect to slow down oscillatory patterns. Rational
for these changes in patterns can be found in the sections that follow.
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Briefly, biogenic amines such as serotonin are transported from the extracellular
space by a variety of transporters.14 The serotonin transporter (SERT) is a high affinity,
low capacity (uptake1) transporter of extracellular serotonin. Other molecules, such as the
dopamine transporter (DAT), the norepinephrine transporter (NET), the plasma
monoamine transporter (PMAT) and organic cation transporters (OCTs), can transport
serotonin in a low affinity, high-capacity fashion (uptake2). Both classes of transporters
are involved in the reuptake of extracellular serotonin into the cell for degradation and
recycling. In the ambient state, these transporters are acting in a delicate balance to perform
this function.
As an atypical antidepressant, ketamine acts primarily through the inhibition of Nmethyl-D-aspartate (NMDA) receptors and pargyline inhibits intracellular monoamine
oxidase20. Considering that the effects of these two antidepressants do not alter the balance
between the uptake1 and uptake2 transporters, it follows that they, in turn, do not alter the
frequency of oscillation in ambient serotonin levels. This is consistent with the data set
above, in figure 3.7C & 3.7D, which shows that there is no change in frequency pre- and
post-administration of ketamine and pargyline.
However, the other drugs administered in this study, escitalopram, fluoxetine and
reboxetine, directly impart their effects on these uptake1 and uptake2 transporters.
escitalopram21, 22 and fluoxetine23 are SERT antagonists, meaning they are inhibiting the
action of uptake1 transporters. To restore balance in this environment, compensatory action
is taken via the uptake2 transporters. Considering the fact that this class of uptake2
transporters functions in a high capacity, low affinity fashion, it suitably follows that the

98

frequency of ambient serotonin oscillations is enhanced. This is consistent with the data
above, in figure 3.7A & 3.7B, in which these two antidepressants increased the oscillatory
frequency following administration.
Finally, reboxetine is a NET antagonist that imparts its action on this uptake2
transporter.24, 25 Because this is inhibiting the activity of this low affinity, high capacity
transporter class, compensatory actions of the high affinity, low capacity SERT likely
occurs. It follows, then, that the frequency of oscillation would decrease with an
upregulation of high affinity, low-capacity transporter activity. This is confirmed in the
data in which the oscillations of ambient serotonin are slowed following administration of
reboxetine in figure 3.7E.
In sum, these two classes of transporters are in a delicate balance in the homeostatic
system, and pharmacological disruption of this balance results in subsequent alterations in
serotonin steady state dynamics. In the present study, we assessed various classes of
antidepressant effects on serotonin oscillations. Clinically, SSRIs are often prescribed on a
“trial-and-error” basis before a pharmaceutical agent proves efficacious in alleviating
symptoms.26 This period of trial-and-error can span months before patients see any
improvement in phenotypic symptoms.27 Imbalances in extracellular serotonin are
hypothesized to cause the adverse symptoms seen in depression, but the origin of this
imbalance is unknown.28 It makes sense, then, that some classes of antidepressants are
particularly efficacious in some cases of depression while virtually ineffective in others
because the origin of the imbalance is not identical in all cases. Thus, this data explicitly
confirms that these antidepressants are variable even in their effects on ambient serotonin
dynamics. Pertinent consideration of these differing effects is necessary in understanding
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the clinical efficacy or inefficacy of antidepressant compounds. In addition, this
phenomenon should be evaluated in screening compounds during the drug discovery
process.
Ultimately, we have shown that FSCAV is powerful, versatile and able to
visualize fine changes in extracellular ambient serotonin levels. Though these frequency
changes are not statistically significant, they are promising for future studies. By
combining the efforts to speed up the data acquisition rate we will further surpass the
Nyquist limit, and thus our new sample rate will allow us to enhance the definition of
oscillatory patterns in the ambient state. Proof of principle studies for speeding up the
acquisition are below.
For each adjusted FSCAV time parameter, the in vitro signals of serotonin were
plotted against time to visualize oscillations associated with the technical noise. The
average frequency and amplitude were quantified from the concentration vs. time graphs
for each parameter. A two-tailed t-test was conducted to determine statistical significance
at p-values of 0.05, 0.025, and 0.001. The optimized FSCAV time parameter was defined
as the shortest time at which frequency was maximized and amplitude was minimized when
compared to the original FSCAV time parameter.
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Background Time

Figure 5.4: Background Time. Average technical noise frequency (blue) and amplitude
(purple) for background time adjusted from 2 s to 1 s
The average frequency (blue) for 2 s background time is 10.00 ± 1.0 mHz (Figure
5.4). The average frequency for 1 s background time is 9.67 ± 0.9 mHz (Figure 5.4). The
average technical noise frequency does not significantly increase or decrease when the
background time is adjusted from 2 s to 1 s for serotonin. Since frequency does not change,
the background time parameter may be adjusted to 1 s depending on the amplitude effects
of the time adjustment. The average amplitude (purple) for 2 s background time is 0.20 ±
0.05 pC (Figure 5.4). The average amplitude for 1 s background time is 0.08 ± 0.03 pC
(Figure 5.4). The amplitude of the technical noise significantly decreases when the
background time is adjusted to 1 s. Because amplitude is minimized and frequency is
maintained at a maximum, the FSCAV background time for serotonin can definitively be
reduced to 1 s.
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Controlled Adsorption Time

Figure 5.5: Controlled Adsorption Time. Average technical noise frequency (blue) and
amplitude (purple) for controlled adsorption time adjusted from 10 s to 5 s and 1 s
The average frequency (blue) for 10 s controlled adsorption time is 10.33 ± 1.1
mHz. The average frequency for 5 s controlled adsorption time is 9.67 ± 0.9 mHz, the
average frequency for 1 s controlled adsorption time is 10.00 ± 1.0 mHz (Figure 5.5). The
average technical noise frequency does not significantly change when the controlled
adsorption time is adjusted from 10 s to 1 s for serotonin. Since frequency is not
significantly affected, the controlled adsorption time parameter may be adjusted to 1 s
depending on the amplitude effects of the time adjustment. The average amplitude (purple)
for 10 s controlled adsorption time is 0.17 ± 0.09 pC, the average amplitude for 5 s
controlled adsorption time is 0.13 ± 0.09 pC, the average amplitude for 1 s controlled
adsorption time is 0.08 ± 0.03 pC (Figure 5.5). The amplitude of the technical noise
significantly decreases when the controlled adsorption time is adjusted to 1 s. Because
amplitude is minimized and frequency is maintained at a maximum, the FSCAV controlled
adsorption time for serotonin can be reduced to 1 s. It is important to note that during
controlled adsorption time, serotonin must reach an equilibrium concentration when
adsorbed onto the surface of the microelectrode. A series of flow injection analysis
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experiments must be conducted in vitro to verify that maximum adsorption can be reached
within 1 s before the time parameter is modified for in vivo experiments.
Redox Time

Figure 5.6: REDOX Time. Average technical noise frequency (blue) and amplitude
(purple) for redox time adjusted from 18 s to 12 s and 6 s
The average frequency (blue) for 18 s redox time is 10.33 ± 1.5 mHz, average
frequency for 12 s redox time is 8.00 ± 3.6 mHz and for 6 s redox time is 9.33 ± 0.8 mHz
(Figure 5.6). The average technical noise frequency does not significantly change when
the redox time is adjusted from 18 s to 12s or 6 s for serotonin. Since frequency is not
significantly affected, the controlled adsorption time parameter may be adjusted depending
on the amplitude effects of the time adjustment. The average amplitude (purple) for 18 s
redox time is 0.10 ± 0.01 pC, for 12 s redox time is 0.9 ± 0.02 pC and for 6 s redox time is
0.19 ± 0.04 pC (Figure 5.6). The amplitude of the technical noise is significantly increased
when the redox time is adjusted to 6 s. The amplitude does not significantly change when
the redox time is adjusted to 12 s. Because amplitude is minimized and frequency is
maintained at a maximum at 12 s redox time, the FSCAV redox time for serotonin can be
reduced to 12 s.

103

Wait Time

Figure 5.7: Wait Time. Average technical noise frequency (blue) and amplitude (purple)
for wait time adjusted from 30 s to 15 s and 0 s
The average frequency (blue) for 30 s wait time is 10.00 ± 1.9 mHz (Figure 5.7).
The average frequency for 15 s wait time is 10.80 ± 2.1 mHz (Figure 5.7). The average
frequency for 0 s wait time is 9.60 ± 1.7 mHz (Figure 5.7). The average technical noise
frequency does not significantly change when the wait time is adjusted from 30 s to 15 s
or 0 s for serotonin. Since frequency is not significantly altered, so the wait time parameter
may be adjusted depending on the amplitude effects of the time adjustment. The average
amplitude for 30 s wait time is 0.11 ± 0.04 pC (Figure 5.7). The average amplitude for 15
s wait time is 0.10 ± 0.04 pC (Figure 5.7). The average amplitude (purple) for 0 s wait
time is 0.10 ± 0.03 pC (Figure 5.7). The amplitude of the technical noise is maintained at
a minimum across all time adjustments. The amplitude does not significantly change when
the wait is adjusted to 0 s. Because amplitude is minimized and frequency is maintained at
a maximum at 30 s, the FSCAV wait time for serotonin can be eliminated.
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Optimized File Times for Serotonin
A total optimized FSCAV file time was determined for serotonin. The background
time was reduced to 1 s, the controlled adsorption time was reduced to 1 s, the redox time
was reduced to 12 s and the wait time was reduced to 0 s.
CONCLUSIONS
We can tease out fundamental differences in serotonin patterns—thus alluding to
transporter class mediation of steady state serotonin. The temporal resolution of FSCAV
can be increased for serotonin through the optimization of background, controlled
adsorption, redox and wait time parameters. Compared to the original FSCAV file time
of 60 seconds our new optimized time is 14 secs, trimming over 3/4ths of the time of the
original data acquisition time. Ultimately, the optimized file times will allow for faster
data collection and will improve definition of the ambient regulatory patterns for
serotonin by further surpassing the Nyquist limit.

.
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Chapter 6: Conclusions and Outlook
FSCV and FSCAV are advantageous platforms for understanding neuronal
communication and to aid in answering fundamental questions about the brain. These
techniques have shown promise to probe discrete changes in neurochemicals due to their
biocompatibility, rapid data acquisition, selectivity and sensitivity. Over the years, most of
the information about neuronal commutation has centered on monitoring the rapid-fire,
phasic changes in neurotransmission. Recently, tools like FSCAV have been developed to
probe the delicate homeostatic state of the central nervous system to eavesdrop on the
natural tonic state. In this dissertation, we have positioned fast-voltammetry as a unique
technique to understand ambient dynamics of the serotonergic system.
In Chapter 2, we confirmed the formation of an auspicious gluatmate layer formed
on our electrodes surface due to the in vivo environment. We confirmed this
voltammetrically, spectrally and microscopically. We then applied this new, confirmed
coating in order to get a two-fold increase in our serotonin stimulated detection. Ultimately,
we have shown that these improvements to sensitivity our due to the complex extracellular
matrix. However, we note that glutamate contributes to this robust change, however this
neuromodulator is most likely not the only contributor. This is explored further chapter 3.
In Chapter 3, we describe novel and robust amino acid surface treatment and
alleviate shortcomings of serotonin detection with FSCAV. In short, we show that by
electrochemically pre-treating the electrode surface in a biologically relevant matrix, we
improve upon the equilibrium time before ambient data acquisition. Ultimately, this has
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made FSCAV to be more user-friendly, giving it the opportunity for it to be more widely
used.
In Chapter 4, we investigated classical, modern and novel antidepressant
treatments on the serotonergic system. We compared stimulated and basal data upon drug
administration and saw that no matter the pathway of action, there are direct or downstream
effects on serotonin We also explored the downstream effects of ketamine administration
on the histaminergic system. Finally, we showed the promise for a novel drug, seleniumfluoxetine, as an alternative antidepressant treatment via phasic release.
In Chapter 5, we utilized FSCAV to understand the regulatory mechanisms of
ambient serotonin oscillations. We introduce FSCAV as a tool to understand the tight
regulatory processes of serotonin oscillations. We first verified that FSCAV does indeed
detect small fluctuations in ambient serotonin levels. We proposed a rationale for these
tight fluctuations in ambient serotonin via pharmacological and mathematical
manipulations and show that ambient levels are heavily regulated by reuptake transporters.
Upon confirmation, we set to improve our data acquisition time to better define these
changes. We systemically confirmed that we can improve the temporal resolution of
FSCAV from 60 s to 14 s files.
Our future plans for the continuation of this work are three-fold:
1. Continue efforts to improve FSCAV data collection with further surface
modification to the CFMs s and applying them to in vivo analysis.
2. Understand the fundamental changes to ambient serotonin upon the administration
of pargyline.
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3. Verify and utilize optimized FSCAV data acquisition time and apply in vivo to
better understand and probe biological oscillations of serotonin.
Overall, this dissertation has setup FSCAV as a powerful and versatile method for
ambient analysis of the serotonin system. We have improved this technique via surface
modification and acquisition time, and have probed and pharmacologically
manipulated the serotonergic pathway to understand underlying mechanisms of
control. These fundamental studies have ultimately improved analysis of ambient
serotonin, and in doing so, we have laid the groundwork to answer fundamental
biological questions in the future.
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Figure A.1: Pre- and Post-calibration Effects. Current (nA) or charge (pC) response to
various concentrations of dopamine is plotted. (A) A pre-calibration was performed with
FSCV, followed by implantation of the electrode in vivo for 20 min, and a post-calibration
was performed after removal (n=5). All pre-calibrations are denoted in red and postcalibrations are denoted in blue. (B) A bare electrode is pre-calibrated with FSCV, then
the DA waveform is cycled for 2 hours in PBS buffer, followed by a post-calibration (n=5).
(C) The experimental paradigm is repeated with FSCAV where the electrode is precalibrated, cycled for 2 hours in TRIS buffer, and post-calibrated. These experiments were
performed as a control (n=4). (D) A table of compiling data from Figure 1 and Figure S1
of experimental and control, FSCV, and FSCAV trails. Statistics: Error bars represent
standard error of the mean. P-value was determined with a one-way paired T-test, ns = not
significant.
To further support the results from Fig. 2.1, control pre-calibrations and post-calibrations
were performed in Fig. A.1. When electrodes were implanted into brain tissue for between
20 minutes (to simulate the routine in vivo conditioning protocol) and 2 hours (the length
of a typical in vivo experiment), there were significant increases in the slopes of postcalibrated electrodes with both FSCV and FSCAV, as shown in both Fig. A.1 and Fig. 2.1.
Electrodes were cycled for 2 hours with the DA waveform (+1.3 V positive potential limit)
and calibrated before and after. When electrodes were cycled in PBS buffer for two hours,
there was no change in the slope of the calibration curves before and after analysis with
both FSCV and FSCAV. The percent increase in slope for each plot in Fig. A.1 and Fig.
2.1, as well as the significance of each experiment, is compiled in the table within Fig.
A.1.D. From these results, we conclude that the in vivo environment must be responsible
for the increase in sensitivity, as the use of two different buffers and application of over-
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oxidizing potential over time did not result in significant increases in the slopes of control
calibration curves.

Figure A.2: Pre- and Post-Glutamate Polymerization Effects—FSCAV Analysis.
Charge (pC) response to 1 µM of DA is displayed in the bar graph above. The red
represents the responses of bare electrodes to 1 µM DA over 15 mins (n=6) of data
acquisition using FSCAV. The bare electrodes were then cycled at 60 Hz on the DA
waveform in a 1µM glutamate solution. The blue represents the responses of the now
electropolymerized electrodes to 1 uM DA over 15 mins (n=6). A paired t-test and an
ANOVA two-way test were performed on this data set; the two factors compared were the
pre- and post-gluatmate polymerization in each test. Both tests indicate that glutamate
polymerization produces a significant difference in sensitivity toward DA detection via
FSCAV (p-value <0.00001).
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1. Beaker Experiments Towards AA Surface Treatment. The following in vitro
experiments were key findings toward the final amino acid surface modification and in
vivo implantation.

Figure B.1: Surface treatments of the carbon fibre with polymerized amino acids.
(A, B, C, D, E) In vitro FSCAV acquisitions in PBS-buffered 75 nM serotonin solution
together with the amino acid stated in the graph of each panel. Scatter points and error
bars show the mean ± SEM across 5 electrodes. The gray bar shows the time at which the
polymerization waveform is applied.
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Figure B.2: Surface treatments of the carbon fibre with polymerized amino acids +
wait time experiments. In vitro FSCAV acquisitions in AA acid + PBS-buffer 75 nM
serotonin solution together. Across 3 electrodes, polymerized electrodes held for 10 mins
at 0.2 V were the most stable. Below, current vs. time traces of serotonin collected in vivo
are averaged (n=5) and compared: polymer application of the 3 AA pretreatment (blue) vs.
the Jackson waveform on NA electrodes (brown) gray bar shows the time at which the
polymerization waveform is applied.
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Pretreatment with Glutamate:
Carbon fiber micro-electrodes were hand fabricated and cut to 150 microns prior to
coating with Nafion as previously described. The electrode was cycled in physiological
buffer with 1uM glutamate for 10 minutes at 60hz and 10 minutes at 10hz using the
extended Jackson waveform (0.2V to -0.1V to 1.3V to 0.2V at a scan rate of 1000V/s).
After cycling with extended waveform for 20 minutes, the electrode was cycled for
10minutes at 60hz and 10 minutes at 10 Hz using the conventional Jackson waveform in
physiological buffer with 1uM glutamate.
Pretreatment with Glutamate, Glycine, and GABA:
Carbon fiber micro-electrodes were hand fabricated and cut to 150 microns prior to
coating with Nafion as previously described. The electrode was cycled in physiological
buffer with 21.3 uM glutamate, 34uM Glycine, and 2.5uM GABA for 10 minutes at 60hz
and 10 minutes at 10hz using the extended Jackson waveform (0.2V to -0.1V to 1.3V to
0.2V at a scan rate of 1000V/s). After cycling with extended waveform for 20 minutes,
the electrode was cycled for 10minutes at 60hz and 10 minutes at 10 Hz using the
conventional Jackson waveform in physiological buffer with 21.3 uM glutamate, 34uM
Glycine, and 2.5uM GABA
Pretreatment with Glutamate, Glycine, and GABA:
Carbon fiber micro-electrodes were hand fabricated and cut to 150 microns prior to
coating with Nafion as previously described. The electrode was cycled in physiological
buffer with 21.3 uM glutamate, 34uM Glycine, and 2.5uM GABA for 10 minutes at 60hz
and 10 minutes at 10 Hz using the conventional Jackson waveform.
Injection Protocol:
Pretreatment with Glutamate:
Following the Cycling paradigm, a bolus of 1uM serotonin was introduced to the
electrode using the flow injection analysis system 40 times with 2 minutes between each
injection. Between injections, the physiological buffer (with no glutamate) was permitted
to flow through the system into contact with the electrode at a flow rate 1.7ml/min.
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Pretreatment with Glutamate, Glycine, and GABA:
Following the Cycling paradigm, a bolus of 1uM serotonin was introduced to the
electrode using the flow injection analysis system 40 times with 2 minutes between each
injection. Between injections, the physiological buffer, with 21.3 uM glutamate, 34uM
Glycine, and 2.5uM GABA, was permitted to flow through the system into contact with
the electrode at a flow rate 1.7ml/min.
No Pretreatment with Glutamate, Glycine, and GABA:
Following the Cycling paradigm, a bolus of 1uM serotonin was introduced to the
electrode using the flow injection analysis system 40 times with 2 minutes between each
injection. Between injections, the physiological buffer, 21.3 uM glutamate, 34uM
Glycine, and 2.5uM GABA, was permitted to flow through the system into contact with
the electrode at a flow rate 1.7ml/min.
Figure B.3: FSCV confirmation of 3 AA treated electrode
Table B.1: List of names of groups and indexes of the analysis of variance.
Group

Number

Glutamate

1

GABA

2

Glycine

3

Glu + GABA + Gly

4

None (PBS only)

5

Table B.2: Analysis of variance results for the differences between pre and post sensitivity
(Figure 3).
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Treatment

6.8698

4

1.7174

1.1650

0.3558

Error

29.4839

20

1.4742

-

-

Total

36.3537

24

-

-

-

As depicted in Table B.2, no significant effect of the treatment (polymerization of amino
acids into the carbon fibre) was found in the variability of differences in sensitivity pre and
post polymerization.
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Table B3: Analysis of variance results for the differences between pre and post time
constant (Figure 3).
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Treatment

8.4857e+03

4

2.1214e+03

8.2009

4.3827e-04

Error

5.1736e+03

20

25258.6814

-

-

Total

1.3659e+03

24

-

-

-

Table B.3 shows that a significant effect of the factor treatment was found in the variability
of differences in time constant pre and post polymerization. After that, a Tukey-Kramer
post-hoc multiple comparison test was performed. The full matrix of multiple comparisons
p values are shown in Table S.4, and p values in bold are reported in the main manuscript.
Table B.4: Tukey-Kramer post-hoc test across ANOVA groups. Probabilities in bold text
are of interest.
Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean t63% (i) = Mean t63% (j)
i/j

1

2

3

4

5

1

-

0.2334

0.9457

0.9746

0.0005

2

0.2334

-

0.6173

0.5316

0.0636

3

0.9457

0.6173

-

0.9999

0.0028

4

0.9746

0.5316

0.9999

-

0.0021

5

0.0005

0.0636

0.0028

0.0021

-

Table B.5: List of names of groups and indexes of the analysis of variance.
Group

Number

In vivo, Nafion-only electrodes

1

In vivo, AA-polymerized electrodes 2
In vitro in AA matrix

3
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Table B.6: Analysis of variance results for the t63%of experimental traces (Figure 3).
Source

Sum sq.

d.f.

Mean sq.

F statistic

Prob > F

Model

1406.6723

2

703.3362

5.3129

0.0161

Error

2250.5169

17

132.3833

-

-

Total

3657.1892

19

-

-

-

Table B.6 shows that a significant effect of the matrix and electrode surface treatment in
the time constant of the experimental trace. After that, a Tukey-Kramer post-hoc multiple
comparison test was performed. The full matrix of multiple comparisons p values are
shown in Table S.7, and p values in bold are reported in the main manuscript.

Table B.7: Tukey-Kramer post-hoc test across ANOVA groups. Probabilities in bold text
are of interest.
Tukey-Kramer post-hoc multiple tests
Pr > |t| for H0: Mean t63% (i) = Mean t63% (j)
i/j

1

2

3

1

-

0.9663

0.0216

2

0.9663

-

0.0290

3

0.0216

0.0290

-
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